

Weekly

February 24, 2006 / Vol. 55 / No. 7


Mumps Epidemic — United Kingdom, 2004–2005

During 2004–2005, the United Kingdom (UK) experienced a nationwide epidemic of mumps, which peaked during 2005 when 56,390* notified cases were reported in England and Wales. The majority of confirmed cases during 2004–2005 were in persons aged 15–24 years, most of whom had not been eligible for routine mumps vaccination. Mumps usually is a self-limited viral disease that appears as parotitis. However, mumps also can lead to serious complications such as encephalitis or pancreatitis. This report summarizes the epidemiology of the 2004–2005 mumps epidemic in England and Wales.

Reporting was based on notified cases (i.e., clinically diagnosed cases of mumps reported by general practitioners). Since late 1994, laboratory confirmation of all notified cases of mumps has been recommended using a test to detect mumpsspecific IgM antibodies in either serum or an oral fluid (1). The proportion of such cases began to increase in 1999 and increased further in each subsequent year, indicating an increase in the incidence of true infection.

The number of notified cases began increasing in 2003 and continued to increase during 2004–2005, accompanied by further increases in the proportion of confirmed cases (Figure 1). During 2004, a total of 16,367 cases were notified; 10,641 (65.0%) of these were tested for oral fluid IgM, and 6,047 of those cases (56.8%) were determined to be IgM positive. When combined with those cases confirmed by serum IgM testing, a total of 8,128 (49.7%) cases were laboratory confirmed during 2004, compared with 3,907 (29.9%) of 13,087 notified cases during 1999–2003. In February 2005, because of high rates of laboratory confirmation of cases among persons born during 1981–1986, the UK Health Protection Agency recommended a temporary halt to testing persons with

FIGURE 1. Number of notified* cases of mumps and proportion of cases that were laboratory confirmed^{\dagger} — England and Wales, 2004–2005



* Clinically diagnosed cases of mumps reported by general practitioners. [†] Cases confirmed by measure of mumps-specific IgM in oral fluid samples only. [§] The number of confirmed cases is artificially low from the second 4-week period in 2005 through the end of the year because of this temporary change in the oral fluid testing program.

INSIDE

- 175 Mumps Outbreak at a Summer Camp New York, 2005
- 177 Hypertension-Related Mortality Among Hispanic Subpopulations — United States, 1995–2002
- 180 Multistate Outbreak of Salmonella Typhimurium Infections Associated with Eating Ground Beef — United States, 2004
- 183 Update: Influenza Activity United States, February 5–11, 2006
- 185 Notice to Readers
- 185 QuickStats

^{*} Provisional total.

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION

Centers for Disease Control and Prevention. [Article title]. MMWR 2006;55:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH Director

Dixie E. Snider, MD, MPH Chief Science Officer

Tanja Popovic, MD, PhD Associate Director for Science

Coordinating Center for Health Information and Service

Steven L. Solomon, MD Director

National Center for Health Marketing

Jay M. Bernhardt, PhD, MPH Director

Division of Scientific Communications

Judith R. Aguilar (*Acting*) *Director*

Mary Lou Lindegren, MD Editor, MMWR Series

Suzanne M. Hewitt, MPA Managing Editor, MMWR Series

Douglas W. Weatherwax (Acting) Lead Technical Writer-Editor

> Stephanie M. Neitzel Jude C. Rutledge *Writers-Editors*

Lynda G. Cupell Malbea A. LaPete Visual Information Specialists

Quang M. Doan, MBA Erica R. Shaver Information Technology Specialists


Notifiable Disease Morbidity and 122 Cities Mortality Data

Patsy A. Hall Deborah A. Adams Lenee Blanton Felicia J. Connor Rosaline Dhara Pearl C. Sharp notified cases of mumps born during those years (2), although persons in other age groups with lower rates of confirmation continued to be tested. Testing for all age groups resumed in January 2006 after a sustained decline in the number of notified cases in the last quarter of 2005.

During 2004, approximately 79.1% of confirmed cases were in persons aged 15–24 years. Among all mumps patients during 2004, approximately 3.3% were reported as having received 2 doses of measles, mumps, and rubella (MMR) vaccine, and another 30.1% had received 1 dose of MMR. The number of notified cases of mumps continued to increase through the first 6 months of 2005, with 20,653 cases occurring during the first quarter and 21,981 cases during the second quarter. During the third quarter of 2005, the number of notified cases decreased by 64.0% to 7,907; during the fourth quarter, a further decrease to 5,882 notified cases was observed (Figure 1). During the first month of 2006, notified cases of mumps averaged approximately 500 per week.

During 2005, the majority of notified mumps cases were in persons aged 19–23 years and attending colleges or universities (Figure 2); the third-quarter decrease in the number of notified cases coincided with summer vacations. Local health services have been encouraged by the UK Health Protection Agency to ensure that all students have received 2 doses of MMR before leaving school. In addition, many universities have advised enrolling first-year students to receive MMR vaccination before arriving at college.

FIGURE 2. Number of notified* cases of mumps, by patient age — England and Wales, 2004–2005^{\dagger}



* Clinically diagnosed cases of mumps reported by general practitioners. † Excludes 200 cases in 2004 and 784 in 2005 with patient date of birth unknown and 1,162 cases in 2004 and 4,404 in 2005 in persons aged >35 years. **Editorial Note:** In October 1988, mumps vaccination was added to the UK vaccination schedule as part of the new combined MMR vaccine. MMR replaced single measles vaccine offered at age 12–15 months; since 1996, a second dose of MMR has been offered at age 3.5–5 years. Vaccination coverage in the UK peaked during 1995, when 92% of children aged 2 years were reported as having received at least 1 dose of MMR. As of the second quarter of 2005, vaccination coverage with at least 1 dose by age 2 years had declined to 82%, with 75% of children having received 2 doses by age 5 years.

During November 1994, approximately 8 million school children aged 5–16 years (i.e., born during September 1978– August 1989) were offered combined measles-rubella vaccine to prevent a predicted epidemic of measles. At that time, a global shortage prevented offering MMR to this group. Therefore, a proportion of the 8 million children remained susceptible to mumps. Modelling based on serologic surveillance data for 1993 estimated that 19% of children aged 11–15 years in 1997 (i.e., aged 19–23 years in 2005) would be susceptible to mumps (4).

The 2004–2005 mumps epidemic in the UK did not result from the decrease in MMR vaccination coverage in recent years, but rather from gaps in eligibility of certain cohorts, which has been evident during the epidemic by the age breakdown among patients with confirmed cases; mumps occurred predominantly in older teens and young adults, with the highest attack rate occurring in those born during 1983–1986 (3). Persons born before September 1987 generally were not eligible for any routine mumps vaccination, although some might have received 1 dose of MMR upon school entry as part of a catch-up campaign after October 1988 that targeted children who missed their measles vaccination. Persons born before 1982 are more likely to have been exposed to mumps infection when it was still a common childhood disease. Only 2.4% of confirmed cases in 2004 occurred in persons who would have been eligible for 2 doses of MMR routinely.

The UK epidemic illustrates the susceptibility of certain cohorts who have not been vaccinated and have not developed immunity through exposure to mumps because of a decrease in mumps circulation after implementation of a childhood immunization program. The epidemic also underscores the importance of ensuring high levels of mumps immunity among adolescents and young adults when vaccination with mumps-containing vaccine is introduced into the routine immunization schedule for children.

References


- Ramsay ME, Brown DEW, Eastcott HR, Begg NT. Saliva antibody testing and vaccination in a mumps outbreak. CDR (Lond Engl Rev) 1991;1:R96–8.
- 2. Changes in laboratory testing as the increase in mumps cases in England and Wales continues. CDR Weekly 2005;15(5).
- 3. Savage E, Ramsay M, White J, et al. Mumps outbreaks across England and Wales in 2004: observational study. BMJ 2005;330:1119–20.
- Gay N, Miller E, Hesketh L. Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Commun Dis Rep CDR Rev 1997;7:R21–6.

Mumps Outbreak at a Summer Camp — New York, 2005

On July 26, 2005, the Sullivan County Health Department (SCHD) and the New York State Department of Health (NYSDOH) were notified of a cluster of cases of parotitis among campers and staff members at a summer camp. An investigation conducted by NYSDOH identified 31 cases of mumps, likely introduced by a camp counselor who had traveled from the United Kingdom (UK) and had not been vaccinated for mumps. This report summarizes the results of the subsequent investigation by NYSDOH, which determined that, even in a population with 96% vaccination coverage, as was the case with participants in the summer camp, a mumps outbreak can result from exposure to virus imported from a country with an ongoing mumps epidemic.

Camp was in session during June 28–August 18. A case of mumps was defined as unilateral or bilateral parotitis of >2 days' duration with no other apparent cause in a camper or staff member who was examined during June 30– September 1, 2005 (1). Among 541 campers and staff members, 31 cases of mumps were identified (attack rate: 5.7%), with illness onsets during June 30–August 9 (Figure). The index patient was a man aged 20 years who resided in the UK and who had not been vaccinated for mumps. The man came to the United States on June 19 to work as a counselor at the camp; on June 30, he had left-sided parotitis, sore throat, and a low-grade fever. However, mumps was not considered as a diagnosis by health-care staff members at the infirmary.

The patient was not isolated and continued to work among the camp population. During July 15–23, a total of 25 additional cases of parotitis were identified, consistent with exposure beginning June 28. However, the diagnosis of mumps was not made by members of the health-care staff at the infirmary or by community health-care providers for any patient with parotitis until July 24. SCHD and NYSDOH were alerted to a possible outbreak on July 26, and diagnosis of mumps for the first 23 (74%) cases was made via retrospective chart FIGURE. Number* of cases of mumps at a summer camp, by date of onset and participant status — New York, June 30– August 9, 2005



review by NYSDOH on July 27. At that time, five (16%) patients were either symptomatic or in isolation. Subsequently, an additional three (10%) cases were identified, beginning on August 2.

Of the 31 mumps cases identified, 17 (55%) were in females. All patients had parotitis, 24 (77%) had jaw pain, and eight (26%) had bilateral disease. Four male patients had unilateral orchitis; all recovered spontaneously. Specimens for serology and viral culture/nucleic acid detection (i.e., nasopharyngeal swabs and urine) were obtained from six patients. All six serologic specimens tested positive for mumps-specific IgM; however, no virus was successfully amplified or cultured from any clinical specimen.

Twelve (39%) of the 31 mumps cases were among campers (Figure). All were U.S. residents aged 10-15 years who had been vaccinated with 2 doses of measles, mumps, and rubella (MMR) vaccine after the first birthday. Nineteen (61%) of the mumps cases were among staff members; of these, nine (47%) were UK residents, five (26%) were U.S. residents, three (16%) were residents of Australia, and two (11%) were residents of Germany. Staff members with mumps ranged in age from 19 to 41 years (median: 21 years). Of the 17 staff members with mumps for whom vaccination history could be obtained by vaccination or medical record, nine (53%) had not been vaccinated for mumps, four (24%) had been vaccinated with 1 dose, and four (24%) had been vaccinated with 2 doses of a mumps-containing vaccine. Symptoms, illness duration, and complications (e.g., orchitis) did not differ substantially between vaccinated and unvaccinated patients.

Outbreak-control measures were instituted at the camp immediately after SCHD and NYSDOH were notified on July 26. Persons exhibiting signs or symptoms of mumps were isolated from other campers and staff members for 9 days after onset of symptoms. A total of 513 persons who were neither known to have mumps nor symptomatic for mumps were quarantined to the grounds of the camp; these persons were not permitted to enter or leave the camp until their mumps immunity status had been verified. Mumps immunity was assessed in accordance with Advisory Committee on Immunization Practices (ACIP) criteria as follows: 1) birth before 1957, 2) history of physician-diagnosed mumps before arriving at camp, 3) laboratory evidence of mumps immunity (i.e., positive for mumps-specific IgG), or 4) receipt of 1 dose of a mumps-containing vaccine on or after the first birthday, as documented by a health-care provider (1). Twenty persons who could not verify their vaccination status and did not meet any other immunity criteria had their sera tested for mumps-specific IgG.

A total of 73 persons without immunity or with a record of 1 dose of mumps-containing vaccine were administered MMR vaccine. Mumps information was provided to camp personnel, and alerts were distributed to health-care providers statewide. Letters from NYSDOH, written in collaboration with the camp operators, were sent to the parents of campers and directors of other New York camps. After August 9, 2005, no further reports of mumps disease were received at the camp, in the county where the camp was located, or in any U.S. counties of origin for campers and staff members.

Reported by: *K Henry, Sullivan County Health Dept; L Pollock, MSN, C Schulte, D Blog, MD, P Smith, MD, New York State Dept of Health. G Dayan, MD, National Immunization Program; J Schaffzin, MD, EIS Officer, CDC.*

Editorial Note: Mumps generally is a mild and self-limited viral infection; an estimated 15%-20% of infections are asymptomatic. However, infections occasionally can lead to serious complications, with or without parotitis. Meningitis occurs in an estimated 15% of cases, of which a small percentage can progress to encephalitis and permanent central nervous system sequelae; pancreatitis is observed in approximately 4% of cases and sensorineural deafness in an estimated one in 20,000 cases (2). First-trimester mumps infection in pregnant women is associated with a 25% incidence of spontaneous abortion (2). In addition, mumps causes orchitis in approximately 40% of postpubertal males, with infertility as a rare consequence (2). The number of mumps cases reported annually in the United States ranged from 231 to 277 cases during 2001-2005. However, mumps remains endemic in many countries throughout the world, and mumps vaccine is used in only 57% of World Health Organization membercountries, predominantly in countries with more developed economies (2,3).

Mumps vaccine was first licensed in the United States in 1967; vaccination with at least 1 dose of mumps-containing vaccine has been required for school entry in New York since 1986. MMR vaccination coverage in the United States has been estimated at >90% among children aged 19–35 months since 1994.* During 2004–2005, estimates of immunity to mumps in New York, according to ACIP criteria, were 96% in schools and 98% in post-secondary institutions (D. Gonzalez, NYSDOH Immunization Program, personal communication, 2006).

Previous investigations of mumps outbreaks reported similar clinical symptoms among vaccinated and unvaccinated patients (4). With the decrease in mumps incidence in the United States, health-care providers have become less likely to suspect mumps in patients with parotitis. In the camp outbreak, although patients were evaluated by multiple healthcare providers, including camp and hospital physicians, parotitis was not recognized as mumps until well into the outbreak. Providers, parents, and child-care and school staff members need to be aware of mumps signs and symptoms, potential complications, and communicability and the need to suspect mumps regardless of patient vaccination status. In addition, given the low prevalence of mumps in the U.S. population, laboratory confirmation should be encouraged to diagnose mumps accurately (5, 6).

In the camp outbreak, mumps likely was introduced by an unvaccinated counselor who traveled from the UK, where an epidemic of mumps was ongoing, with 56,390 notified cases reported during 2005 in England and Wales (7). The likelihood of disease in U.S. residents as a result of imported virus from areas with mumps epidemics remains high (5). Vaccination of counselors who will be working in summer camps is recommended, particularly because mumps vaccine effectiveness can be <85% in outbreak settings (4,8,9). As a result of this outbreak, agencies involved in assigning foreign staff to U.S. camps and organizations of camp administrators have begun revising their admission requirements to include immunity to vaccine-preventable diseases such as mumps.

The outbreak described in this report likely resulted from a combination of delay in diagnosis of mumps and failure to report the cluster of illnesses in a timely manner, in addition to close contact and social mixing among camp participants. Controlling the outbreak resulted in a substantial burden on the camp and its staff, including cancellation of activities and likely loss of revenue. Previous mumps outbreaks also have carried substantial burden, particularly with respect to costs associated with school absenteeism (9). To prevent large outbreaks of mumps in their communities, U.S. health-care pro-

viders should suspect mumps independent of vaccination history, diagnose mumps by using laboratory testing, and report mumps immediately to local health authorities.

Acknowledgments

The findings in this report are based, in part, on contributions from staff of the New York State Dept of Health Immunization Program; and from C LeBaron, MD, National Immunization Program, and L Lowe and N Williams, National Center for Infectious Diseases, CDC.

References

- CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(No. RR-8).
- Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999;77:3–14.
- World Health Organization. Global status of mumps immunization and surveillance. Wkly Epidemiol Rec 2005;80:418–24.
- Hersh BS, Fine PE, Kent WK, et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991;119:187–93.
- 5. Bloom S, Wharton M. Mumps outbreak among young adults in UK. BMJ 2005;331:E363–4.
- 6. Guy RJ, Andrews RM, Kelly HA, et al. Mumps and rubella: a year of enhanced surveillance and laboratory testing. Epidemiol Infect 2004;132:391-8.
- 7. CDC. Mumps epidemic—United Kingdom, 2004–2005. MMWR 2006;55:173–5.
- Harling R, White JM, Ramsay ME, Macsween KF, Van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005;23:4070–4.
- 9. Wharton M, Cochi SL, Hutcheson RH, Bistowish JM, Schaffner W. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988; 158:1253–60.

Hypertension-Related Mortality Among Hispanic Subpopulations — United States, 1995–2002

Hypertension remains a major public health problem in the United States even though effective therapy has been available for more than 50 years (1). Hypertension is a strong independent risk factor for heart disease and stroke and a predictor of premature death and disability from cardiovascular complications (2). Although age-adjusted prevalence of hypertension is lower among Hispanics than among blacks or non-Hispanic whites (3–5), recent data indicate that certain Hispanic subpopulations (Mexican Americans, Puerto Rican Americans, Cuban Americans, and other Hispanic Americans) are characterized by low levels of hypertension awareness, treatment, and control. Because Hispanics are the fastest growing and youngest racial/ethnic population in the United States (6), targeted strategies to reduce morbidity and mortality rates among this population are essential. Since 1995, information

^{*} National Immunization Surveys, 1994–2004. Available at http://www.cdc.gov/ nip/coverage/default.htm#nis.

on Hispanic ethnicity has been provided on nearly all death certificates issued in the United States.* Although data on Hispanic subpopulations are also available on death certificates, no national mortality statistics on hypertension-related deaths among specific Hispanic subpopulations have been published. To compare age-standardized, hypertension-related death rates among Hispanic subpopulations, CDC analyzed death certificate data from 1995 and 2002. This report describes the results of that analysis, which indicated that Puerto Rican Americans had consistently higher hypertension-related mortality (HRM) rates than all other Hispanic subpopulations and non-Hispanic whites. Comprehensive hypertension prevention and control programs are needed to target these Hispanic subpopulations.


National death certificate data were obtained from the multiple cause-of-death files compiled by CDC. Most analyses of mortality data are based on the underlying cause of death (i.e., the disease or injury that initiated the sequence of events leading directly to death). However, hypertension is not only an important underlying cause of death but also is a common complicating factor for other disease. Therefore, in this report, hypertension-related mortality (HRM) includes those deaths for which hypertension (International Classification of Diseases, Ninth Revision (ICD-9) codes 401-404 for 1995 and ICD-10 codes I10-I13 for 2002) was reported either as the underlying cause or as a contributory cause of death (i.e., a condition reported on the death certificate other than the underlying cause). Included are deaths attributed to essential hypertension (i.e., high blood pressure with no identifiable cause), hypertensive heart disease, hypertensive renal disease, hypertensive heart and renal disease, and secondary hypertension. This report was limited to deaths occurring in the 50 states and the District of Columbia among U.S. residents aged ≥ 25 years. Age-standardized death rates based on the 2000 U.S. standard population were estimated for non-Hispanic whites, Hispanics, and four Hispanic subpopulations (Mexican Americans, Puerto Rican Americans, Cuban Americans, and other Hispanic Americans). Population denominators from the U.S. Census Bureau used to calculate death rates included postcensal estimates of the U.S. resident population for 2002 and intercensal population estimates for 1995. The change in HRM from 1995 to 2002 among Hispanic subpopulations was defined as the percentage change in age-standardized death rates. Non-Hispanic whites were the referent group for all estimates of HRM disparity.


In 2002, a total of 13,526 hypertension-related deaths were reported among all Hispanics, compared with 209,833 among all non-Hispanic whites. The age-standardized HRM rate was 127.2 per 100,000 population for all Hispanics, similar to that of non-Hispanic whites (135.9). The age-standardized HRM rate for Hispanic women (118.3) was substantially lower than that observed for Hispanic men (135.9) (Table). Male HRM rates were higher than female rates for all Hispanic subpopulations. Puerto Rican Americans had the highest death rate among all Hispanic subpopulations (154.0), and Cuban Americans had the lowest (82.5). Compared with non-Hispanic whites, Puerto Rican Americans had 13% (p<0.01) higher age-standardized HRM rates; other Hispanic Americans were 12% (p<0.01) higher. Age-standardized HRM rates for Cuban Americans were 39% lower (p<0.01) than those for non-Hispanic whites. Rates for Mexican Americans did not differ significantly from non-Hispanic whites (95% CI = 0.97-1.01) (Figure 1).

TABLE. Number and age-standardized rate* of hypertensionrelated deaths among Hispanics aged \geq 25 years, compared with non-Hispanic whites, by sex and subpopulation — United States, 2002

Characteristic	No. of deaths	Rate
All Hispanics	13,526	127.2
Sex		
Male	6,477	135.9
Female	7,049	118.3
Hispanic subpopulation		
Mexican American	7,662	134.5
Puerto Rican American	1,901	154.0
Cuban American	1,264	82.5
Other Hispanic American	2,699	152.4
Non-Hispanic whites	209,833	135.9

* Per 100,000 population.





* 95% confidence interval.

[†]p<0.01.


^{*}Oklahoma did not provide this information until 1997.

In 1995, age-standardized HRM rates (per 100,000 population) were highest among Puerto Rican Americans (159.9), followed by non-Hispanic whites (107.4), other Hispanic Americans (104.3), Mexican Americans (102.9), and Cuban Americans (87.0) (Figure 2). HRM rates increased for Mexican and other Hispanic Americans but decreased for Puerto Rican and Cuban Americans. The greatest percentage increase from 1995 to 2002 was 46.1% (p<0.01) for other Hispanic Americans, followed by increases of 30.7% (p<0.01) for Mexican Americans and 26.5% (p<0.01) for non-Hispanic whites. A 5.2% (p<0.01) decrease occurred from 1995 to 2002 among Cuban Americans, and a 3.7% decrease was observed among Puerto Rican Americans.

Reported by: C Ayala, PhD, MR Moreno, MPH, JA Minaya, MPH, JB Croft, PhD, GA Mensah, MD, Div of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion; RN Anderson, PhD, National Center for Health Statistics, CDC.

Editorial Note: HRM rates increased substantially in the United States during 1995–2002, especially among the Hispanic population. This trend is most evident among Mexican Americans and other Hispanic Americans, who experienced the greatest percentage increases in HRM from 1995 to 2002. Although their HRM rate decreased slightly from 1995 to 2002, Puerto Rican Americans had the highest death rates during all years surveyed, compared with other Hispanic subpopulations and non-Hispanic whites. The higher HRM rates among Puerto Ricans might be the result of greater prevalence of the classic risk factors for hypertensive conditions, including diabetes mellitus, obesity, and physical inactivity in this population. Compared with non-Hispanic whites, Mexi-

FIGURE 2. Age-standardized, hypertension-related mortality rates^{*} and relative percentage changes among adults aged \geq 25 years for non-Hispanic whites and selected Hispanic subpopulations — United States, 1995 and 2002



can Americans have a three- to five-fold higher incidence of diabetes mellitus and a three-fold higher prevalence of obesity (4); however, their HRM rates are only 4% higher than that of whites. In addition, Mexican American (39%) and Cuban American (34%) women are nearly as likely to be overweight as Puerto Rican American women (37%); however, they have lower HRM rates (7). Because diabetes and overweight are risk factors for hypertension, these higher prevalences could place these populations at higher risk for HRM in the future.

The Hispanic population is estimated to account for approximately 13% (35.3 million) of the total 2000 U.S. population. On the basis of current trends, the Hispanic population is projected to increase 2% per year until 2030 and will account for 25% (81 million) of the total U.S. population by 2050. Similar demographic trends have also been projected for Hispanic subpopulations (*3*).

A recent study revealed that, among hypertensive persons, Mexican Americans were less likely than non-Hispanic whites to be treated for hypertension (35% versus 49%, respectively) (5). Hispanics, although generally thought to have lower blood pressure as a population, received therapy for their hypertension in clinics only 50% of the time, and thus were at increased risk for HRM (8). Moreover, untreated hypertension elevates risk for mortality and morbidity from diseases of the heart and stroke, the first and third leading causes of death in the United States, respectively (9).

The findings of this study are subject to at least two limitations. First, the multiple-cause mortality data are subject to errors in the certification of cause of death and in the reporting of Hispanic origin and Hispanic subpopulations. Prob-

> lems associated with the underreporting of Hispanic origin on death certificates and undercoverage in population estimates are well documented (10). Second, misreporting and undercoverage might also vary by Hispanic subpopulation. However, the overall quality and completeness of the mortality data from the vital statistics system are a strength of this study.

> Two major Hispanic subpopulations (Mexican Americans and other Hispanic Americans) have HRM rates that have substantially increased from 1995 to 2002. Although HRM rates have also increased 26% in the general non-Hispanic population, the rate of increase for these subpopulations has been higher. Three factors might contribute to this growing burden: the increasing Hispanic population (3), the increased risk for HRM among Hispanics, and the low percentage of hypertensive Hispanics receiving therapy for hypertension (5). Only 45% of U.S. persons with hypertension receive therapy for their condition; this figure is considerably lower

(34%) among Mexican Americans (5). Even fewer Mexican Americans have their hypertension under control (17%), compared with non-Hispanic whites (30%) (5). Awareness, treatment, and control of hypertension among members of these subpopulations is critical if the burden of hypertension and its serious heart disease and stroke sequelae are to be reduced.

References


- CDC. State-specific trends in blood pressure screening and self-reported high blood pressure in the United States—Behavioral Risk Factor Surveillance System, 1990–1999. MMWR 2002;51:456–60.
- Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2506–72.
- 3. Rameriz RR, de la Cruz GP. The Hispanic population in the United States: March 2002. Current population reports 2002; P20-545, Washington, DC: US Census Bureau; 2002.
- Martinez-Maldonado M. Hypertension in Hispanics: comments on a major disease in a mix of ethnic groups. Am J Hypertens 1995;8: 1205–1235.
- CDC. Disparities in prevalence of hypertension, treatment, and control in the United States, 1999–2002. MMWR 2005;54:7–9.
- 6. Aguirre-Molina M, Molina CW, Zambrana RE, eds. Health issues in the Latino community. Boston, MA: Wiley, John & Sons, Inc.; 2001.
- 7. CDC. Topics in minority health prevalence of overweight for Hispanics—United States, 1982–1984. MMWR 1989;38:838–42.
- Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479–86.
- Henderson SO, Bretsky P, DeQuattro V, Henderson BR. Treatment of hypertension in African Americans and Latinos: the effect of JNC VI on urban prescribing practices. J Clin Hypertens 2003;5:107–12.
- Rosenberg HM, Maurer JD, Sorlie PD, et al. Quality of death rates by race and Hispanic origin: a summary of current research, 1999. Hyattsville, MD: US Department of Health and Human Services, National Center for Health Statistics; 1999. Vital Health Stat (128).


Multistate Outbreak of Salmonella Typhimurium Infections Associated with Eating Ground Beef — United States, 2004

Salmonella infections cause an estimated 1.4 million human illnesses and 400 deaths annually in the United States (1). Although the incidence of several other foodborne bacterial infections decreased substantially during 1996–2004, the incidence of Salmonella infections declined modestly (2). In September 2004, the New Mexico Department of Health received reports from the New Mexico Scientific Laboratory Division of eight Salmonella enterica serotype Typhimurium isolates that had indistinguishable pulsed-field gel electrophoresis (PFGE) patterns using XbaI and BlnI restriction enzymes. The patients were from three New Mexico counties and had onsets of illness during August 18–29. A review of PFGE patterns submitted to the National Molecular Subtyping Network for Foodborne Disease Surveillance (PulseNet) database for Salmonella revealed 31 indistinguishable patient isolates of S. Typhimurium from nine states (Colorado, Kansas, Minnesota, New Jersey, New Mexico, New York, Ohio, Tennessee, and Wisconsin) and the District of Columbia, with illness onset occurring during August 11-October 2, 2004. The S. Typhimurium isolates were susceptible to all antimicrobial agents tested. An investigation conducted by state health departments, CDC, and the U.S. Department of Agriculture Food Safety and Inspection Service (FSIS) identified ground beef purchased at a national chain of supermarkets as the source of S. Typhimurium infections. Traceback results indicated product originating from a common supplier; however, evaluators determined that plant practices conformed to FSIS production guidelines, and no product recalls were made. This report describes the investigation and underscores the risk for salmonellosis from contact with contaminated ground beef, despite regulatory directives to reduce Salmonella contamination in beef production. Reduced contamination and consumption of raw or undercooked meat and further education of the food service industry and consumers are critical to reducing foodborne salmonellosis.

A case was defined as infection with S. Typhimurium with a PFGE pattern indistinguishable from the outbreak pattern. Participating health departments (Colorado, Kansas, Minnesota, New Mexico, Ohio, Wisconsin, and District of Columbia) used questionnaires to collect detailed information about patient history of food consumption before illness onset. After careful review of food histories and information on other possible exposures among patients, contaminated ground beef was suspected as the vehicle for this outbreak. Several patients reported having eaten ground beef purchased at the same national chain of supermarkets (chain A). To identify exposures associated with illness and to investigate the source of potentially contaminated ground beef, the participating health departments conducted a case-control study during September 30-October 19, 2004. The case-control study included case-patients from the six states and the District of Columbia and controls identified by sequential telephone digit dialing. The controls were matched by age group (ages 2–10, 11–17, 18-60, and >60 years) to case-patients and had no reported gastrointestinal illness within 7 days before onset of illness of the matched case-patients. Case-patients and controls were asked detailed questions regarding ground beef consumption and brand, location, and date of purchase of ground beef.

Twenty-six of 31 case-patients (Figure) and 46 controls were enrolled in the case-control study. Five patients were not enrolled in the study; three were from states that declined to participate, and two could not be contacted. Fourteen (53.9%) case-patients were female, and the median age was 30.5 years







(range: 2–80 years). Twenty-one (47.7%) controls were female, and the median age was 35 years (range: 2–87 years). Symptoms reported by the case-patients included diarrhea (100%), abdominal cramps (92%), fever (92%), vomiting (65%), and bloody diarrhea (46%). Median duration of illness was 7.5 days (range: 2–30 days); 35% of patients were hospitalized. No patients died.

Of the 26 case-patients, 23 with matched controls were included in the analyses (three with no matched controls were excluded). Among 23 matched case-patients, 21 (91%) reported eating ground beef during the 7 days before illness, compared with 37 (80%) of 46 controls (matched odds ratio [mOR] = 2.4; 95% confidence interval [CI] = 0.5-11.8). Ten (44%) matched case-patients reported eating raw or undercooked ground beef or tasting the beef while cooking, compared with eight (17%) controls (mOR = 7.4; CI = 1.2-44.6). Among 21 case-patients who ate ground beef, 15 (71%) purchased the beef within 3 weeks before illness onset from chain A, compared with nine (24%) controls (mOR = 12.7; CI = 1.6-99.2).

The Minnesota Department of Agriculture tested a sample of leftover frozen ground beef provided by a Minnesota casepatient. The sample yielded *S.* Typhimurium with a PFGE pattern indistinguishable from the outbreak pattern.

For seven case-patients who reported consumption of ground beef purchased at chain A, shopper cards or purchase receipts were used to determine the source of ground beef and its production date. Traceback results indicated that the ground beef was packaged at three processing plants. One supplier common to all three plants was identified, although beef was mixed at the three processing plants with ingredients from other suppliers. Two other case-patients provided approximate dates for when they purchased ground beef at chain A; records indicated that their purchases could have been from one of the three implicated plants with product originating from the common supplier.

FSIS evaluators assessed the three processing plants and their common supplier by reviewing existing FSIS records and internal plant Hazard Analysis and Critical Control Point plans, processes, and records, including microbial analyses conducted by FSIS officers for the relevant production periods. After extensive investigation, evaluators determined that plant practices conformed to current FSIS production guidelines. No products were recalled.

Reported by: A Cronquist, MPH, Colorado Dept of Public Health and Environment. S Wedel, MPH, Minnesota Dept of Health. B Albanese, MD, CM Sewell, DrPH, New Mexico Dept of Health. D Hoang-Johnson, Wisconsin Dept of Health. T Ihry, DVM, US Dept of Agriculture, Food Safety and Inspection Svc. M Lynch, MD, J Lockett, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; N Kazerouni, DrPH, C O'Reilly, PhD, D Ferguson, MD, EIS officers, CDC.

Editorial Note: *Salmonella* species colonize the gastrointestinal tracts of cattle and other animals. Many infected cattle are asymptomatic carriers. Carcasses can become contaminated with *Salmonella* spp. during slaughter operations. Although FSIS has documented a decrease in *Salmonella* spp. in ground beef, from a baseline prevalence of 7.5% in 1996 to 1.6% of 30,984 regulatory samples collected in 2004 (3,4), outbreaks of human *Salmonella* infections associated with ground beef continue to occur.

Investigation of this outbreak of S. Typhimurium infection implicated ground beef, particularly consumption of raw or undercooked ground beef, as the source of infection. Ground beef has been implicated as the vehicle for transmission of Salmonella spp. in previous foodborne outbreaks (5-7). Outbreaks of nontyphoidal Salmonella infections and sporadic illness have been associated with various causes, particularly foods of animal origin (1). Recently, the first multistate outbreak of multidrug-resistant S. Typhimurium phage type DT104 associated with consumption of store-bought ground beef occurred in the northeastern United States (8). Epidemiologic and traceback investigations performed during the outbreak described in this report suggested one common supplier as the source. However, processing plant practices appeared to adhere to current FSIS production guidelines. In light of these findings and the findings from previous salmonellosis outbreak investigations (5–8), regulatory requirements and guidelines along the beef production chain, from farming through consumption, should be reviewed to determine whether current critical control points (i.e., preventive measures to control food safety hazards) and pathogen reduction strategies are adequate for *Salmonella* control.

Although the overall incidence of salmonellosis declined by only 8% from 1996 to 2004, infection with S. Typhimurium declined by 41% (2). A proportion of the decline in the incidence of S. Typhimurium infection might be a consequence of increased pathogen reduction strategies for E. coli O157:H7 in ground beef. In 2003 and 2004, incidence of human infections caused by E. coli O157:H7 declined, according to cases reported to the CDC Foodborne Diseases Active Surveillance Network (FoodNet) (2). This decline in human illness was consistent with declines in E. coli O157:H7 contamination of ground beef reported by FSIS during the same period (9). These declines might have been attributable to multiple interventions by regulators (e.g., USDA's declaration of E. coli O157:H7 as an adulterant in ground beef and a compulsory reassessment of the Pathogen Reduction/Hazard Analysis Critical Control Point plans) and beef industry (e.g., increased product testing, more efficient cleaning and sanitizing of carcasses, and diversion of contaminated product from raw ground-beef manufacturing [9]). Such interventions might have concurrently reduced Salmonella contamination of ground beef and salmonellosis in humans. However, regulatory and industry prevention measures and public health education need to be strengthened to meet the national health objective for reducing Salmonella infection.*

The findings in this report also highlight the importance of using PFGE (10) to identify clusters of illness, particularly for S. Typhimurium. Use of PulseNet to disseminate PFGE subtype data, combined with specific case interview information, allowed for an efficient and timely traceback investigation. State and local health departments should continue to conduct timely epidemiologic investigations of Salmonella cases. Routine subtyping of isolates of common Salmonella spp. serotypes such as S. Typhimurium and comparison of isolate PFGE patterns through PulseNet might help focus limited epidemiologic resources by identifying cases that likely are linked (10). Investigation of Salmonella spp. clusters associated with raw or undercooked ground beef consumption can 1) elucidate the mechanisms and possible sources of contamination of ground beef, 2) help determine whether regulatory requirements for the beef industry are adequate, and 3) help identify control points for reducing Salmonella spp. in the meat supply.

Salmonellosis outbreaks associated with ground beef continue, despite Hazard Analysis and Critical Control Point systems, enhanced adherence to good manufacturing practices, and education of food processors, preparers, and servers at all levels in the food industry and in the home. Targeting interventions at various steps, from beef production through consumption, might help prevent salmonellosis. Consumers should continue to be made aware of the risks associated with eating raw or undercooked ground beef, tasting ground beef during food preparation, and cross-contamination from raw meat to readyto-eat foods, as well as the importance of hand washing after handling raw ground beef.

Acknowledgments

This report is based, in part, on data contributed by D Neises, MPH, Kansas Dept of Health; E Salehi, MPH, A Arendt, MPH, Ohio Dept of Health; S Soubagleh, District of Columbia Dept of Health; M Landen, MD, A Robbins, MPH, D Sena, New Mexico Dept of Health; K Elfering, K Vought, Minnesota Dept of Agriculture; K Holt, DVM, M Karinen, US Dept of Agriculture, Food Safety and Inspection Svc; and M Mueller, MPH, Public Health Prevention Svc Fellow, CDC.

References

- Voetsch AC, Van Gilder TJ, Angulo FJ, et al. FoodNet estimate of the burden of illness caused by nontyphoidal *Salmonella* infections in the United States. Clin Infect Dis 2004;38(Suppl 3):S127–34.
- CDC. Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food—10 sites, United States, 2004. MMWR 2005;54:352–6.
- 3. US Department of Agriculture. *Salmonella* testing of raw meat & poultry products, 1998–2004: progress report. Washington, DC: US Department of Agriculture; 2006. Available at http://www.fsis.usda.gov/science/Progress_Report_Salmonella_Testing_1998-2004/ index.asp.
- US Department of Agriculture. Nationwide Federal Plant Raw Ground Beef Microbiological Survey, August 1993–March 1994. Washington, DC: US Department of Agriculture; 1996. Available at http://www. fsis.usda.gov/OPHS/baseline/rwgrbeef.pdf.
- CDC. Salmonella Typhimurium—Minnesota, Wisconsin, Michigan. MMWR 1972;21:411–6.
- CDC. Outbreak of *Salmonella* serotype Typhimurium infection associated with eating raw ground beef—Wisconsin, 1994. MMWR 1995;44:905–9.
- CDC. Outbreak of multidrug-resistant *Salmonella* Newport—United States, January–April 2002. MMWR 2002;51:545–8.
- Dechet AM, Scallan E, Gensheimer K, et al. Outbreak of multidrugresistant *Salmonella enterica* Typhimurium definitive type 104 infection linked to commercial ground beef, northeastern United States, 2003–2004. Clin Infect Dis 2006;42:747–52.
- Naugle AL, Holt KG, Levine P, Eckel R. Food safety and inspection service regulatory testing program for *Escherichia coli* O157:H7 in raw ground beef. J Food Prot 2005;68:462–8.
- Bender JB, Hedberg CW, Boxrud DJ, et al. Use of molecular subtyping in surveillance for *Salmonella enterica* serotype Typhimurium. N Engl J Med 2001;344:189–95.

^{*} *Healthy People 2010* objective 10-1d is to reduce the incidence of *Salmonella* species infections to 6.8 per 100,000 population.


Update: Influenza Activity — United States, February 5–11, 2006

During February 5–11, 2006,* the number of states reporting widespread influenza activity[†] increased to 13. Twenty-one states reported regional activity, 11 reported local activity, and five reported sporadic activity (Figure 1).[§]

The percentage of specimens testing positive for influenza increased in the United States overall. During the preceding 3 weeks (weeks 4–6), the largest number of isolates were reported from the South Atlantic and Mountain regions. During this time, the percentage of specimens testing positive for influenza ranged from 26.3% and 23.4% in the East North Central and South Atlantic regions, respectively, to 7.4% in

[§] Widespread: Colorado, Connecticut, Florida, Georgia, Kansas, Maryland, New York, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, and Wyoming; regional: Alabama, Alaska, Arkansas, Delaware, Illinois, Indiana, Iowa, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, North Carolina, Oklahoma, Oregon, Rhode Island, South Dakota, and Wisconsin; *local:* Arizona, California, Maine, Montana, Nevada, New Hampshire, New Jersey, New Mexico, North Dakota, Ohio, and Washington; *sporadic:* Hawaii, Idaho, Utah, Vermont, and West Virginia; *no activity:* none; *no report:* Missouri.

FIGURE 1. Estimated influenza activity levels reported by state epidemiologists, by state and level of activity* — United States, February 5–11, 2006



* Levels of activity are 1) widespread: outbreaks of influenza or increases in influenza-like illness (ILI) cases and recent laboratory-confirmed influenza in at least half the regions of a state; 2) regional: outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in at least two but less than half the regions of a state; 3) *local:* outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in a single region of a state; 4) *sporadic:* small numbers of laboratory-confirmed influenza cases or a single influenza outbreak reported but no increase in cases of ILI; and 5) *no activity.*

the Pacific region. The percentage of outpatient visits for influenza-like illness (ILI)[¶] increased during the week ending February 11 and remains above the national baseline.** The percentage of deaths attributed to pneumonia and influenza (P&I) was below the epidemic threshold for the week ending February 11.

Laboratory Surveillance

During February 5–11, World Health Organization (WHO) collaborating laboratories and National Respiratory and Enteric Virus Surveillance System (NREVSS) laboratories in the United States reported testing 2,438 specimens for influenza viruses, of which 455 (18.7%) were positive. Of these, 136 were influenza A (H3N2) viruses, six were influenza A (H1N1) viruses, 280 were influenza A viruses that were not subtyped, and 33 were influenza B viruses.

Since October 2, 2005, WHO and NREVSS laboratories have tested 66,129 specimens for influenza viruses, of which 5,216 (7.9%) were positive. Of these, 5,025 (96.3%) were influenza A viruses, and 191 (3.7%) were influenza B viruses. Of the 5,025 influenza A viruses, 2,378 (47.3%) have been subtyped; 2,351 (98.9%) were influenza A (H3N2) viruses, and 27 (1.1%) were influenza A (H1N1) viruses.

P&I Mortality and ILI Surveillance

During the week ending February 11, P&I accounted for 7.0% of all deaths reported through the 122 Cities Mortality Reporting System. This percentage is below the epidemic threshold^{††} of 8.3% (Figure 2).

The percentage of patient visits for ILI was 2.5%, which is above the national baseline of 2.2% (Figure 3). The percentage of patient visits for ILI ranged from 1.5% in the Pacific region to 4.7% in the West South Central region.

Pediatric Deaths and Hospitalizations

During October 2, 2005–February 11, 2006, CDC received reports of 14 influenza-associated deaths in U.S. residents aged <18 years. Twelve of the deaths occurred during the current

^{*} Provisional data reported as of February 17. Additional information about influenza activity is updated each Friday and is available from CDC at http://www.cdc.gov/flu.


[†] Levels of activity are 1) widespread: outbreaks of influenza or increases in influenza-like illness (ILI) cases and recent laboratory-confirmed influenza in at least half the regions of a state; 2) regional: outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza or increases in ILI cases and recent laboratory-confirmed influenza or increases in ILI cases and recent laboratory-confirmed influenza or increases in ILI cases and recent laboratory-confirmed influenza in a single region of a state; 4) sporadic: small numbers of laboratory-confirmed influenza cases or a single influenza outbreak reported but no increase in cases of ILI; and 5) no activity.

⁵ Temperature of $\geq 100.0^{\circ}F (\geq 37.8^{\circ}C)$ and cough and/or sore throat in the absence of a known cause other than influenza.

^{**} The national baseline was calculated as the mean percentage of visits for ILI during noninfluenza weeks for the preceding three seasons, plus two standard deviations. Noninfluenza weeks are those in which <10% of laboratory specimens are positive for influenza. Wide variability in regional data precludes calculating region-specific baselines; therefore, applying the national baseline to regional data is inappropriate.

^{††} The expected seasonal baseline proportion of P&I deaths reported by the 122 Cities Mortality Reporting System is projected using a robust regression procedure in which a periodic regression model is applied to the observed percentage of deaths from P&I that occurred during the preceding 5 years. The epidemic threshold is 1.645 standard deviations above the seasonal baseline.


FIGURE 2. Percentage of deaths attributed to pneumonia and influenza (P&I) reported by the 122 Cities Mortality Reporting System, by week and year — United States, 2002–2006



* The epidemic threshold is 1.645 standard deviations above the seasonal _baseline.

[†] The seasonal baseline is projected using a robust regression procedure that applies a periodic regression model to the observed percentage of deaths from P&I during the preceding 5 years.

FIGURE 3. Percentage of visits for influenza-like illness (ILI) reported by the Sentinel Provider Surveillance Network, by week — United States, 2003–04, 2004–05, and 2005–06 influenza seasons



* The national baseline was calculated as the mean percentage of visits for ILI during noninfluenza weeks for the preceding three seasons, plus two standard deviations. Noninfluenza weeks are those in which <10% of laboratory specimens are positive for influenza. Wide variability in regional data precludes calculating region-specific baselines; therefore, applying the national baseline to regional data is inappropriate.

influenza season, and two occurred during the 2004–05 influenza season.

During October 1, 2005–February 4, 2006, the preliminary laboratory-confirmed influenza-associated hospitalization rate reported by the Emerging Infections Program^{§§} for children aged 0–17 years was 0.30 per 10,000. For children aged 0–4 years and 5–17 years, the rate was 0.78 per 10,000 and 0.04 per 10,000, respectively. During October 30, 2005–February 4, 2006, the preliminary laboratory-confirmed influenzaassociated hospitalization rate for children aged 0–4 years in the New Vaccine Surveillance Network^{¶¶} was 0.33 per 10,000.

Human Avian Influenza A (H5N1)

No human avian influenza A (H5N1) virus infection has ever been identified in the United States. From December 2003 through February 20, 2006, a total of 170 laboratoryconfirmed human avian influenza A (H5N1) infections were reported to WHO from Cambodia, China, Indonesia, Iraq, Thailand, Turkey, and Vietnam.*** Of these, 92 (54%) were fatal (Table). This represents an increase of one case and one death in Indonesia since February 13, 2006. The majority of infections appear to have been acquired from direct contact with infected poultry. No evidence of sustained human-tohuman transmission of H5N1 has been detected, although rare instances of human-to-human transmission likely have occurred (1).

Reference

 Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-toperson transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333–40.

TABLE. Number of laboratory-confirmed human cases and deaths from avian influenza A (H5N1) infection reported to the World Heal
Organization, by country — worldwide, 2003–2006*

					Year of	of onset				
	2	2003	2	004	2	005	2	006	-	Total
Country	No. of cases	Deaths	No. of cases	Deaths	No. of cases	Deaths	No. of cases	Deaths	No. of cases	Deaths
Cambodia	0	0	0	0	4	4	0	0	4	4
China	0	0	0	0	8	5	4	3	12	8
Indonesia	0	0	0	0	17	11	9	8	26	19
Iraq	0	0	0	0	0	0	1	1	1	1
Thailand	0	0	17	12	5	2	0	0	22	14
Turkey	0	0	0	0	0	0	12	4	12	4
Vietnam	3	3	29	20	61	19	0	0	93	42
Total	3	3	46	32	95	41	26	16	170	92

* As of February 20, 2006.

^{§§} The Emerging Infections Program (EIP) Influenza Project conducts surveillance in 60 counties associated with 12 metropolitan areas: San Francisco, California; Denver, Colorado; New Haven, Connecticut; Atlanta, Georgia; Baltimore, Maryland; Minneapolis/St. Paul, Minnesota; Albuquerque, New Mexico; Las Cruces, New Mexico; Albany, New York; Rochester, New York; Portland, Oregon; and Nashville, Tennessee.

⁵⁵ The New Vaccine Surveillance Network (NVSN) conducts surveillance in Monroe County, New York; Hamilton County, Ohio; and Davidson County, Tennessee.
*** Available at http://www.who.int/csr/disease/avian_influenza/en.


Notice to Readers

Release of Computer-Based Case Study: Gastroenteritis at a University in Texas

A new computer-based case study, "Gastroenteritis at a University in Texas," is now available from CDC. Based on an actual outbreak investigation, this self-instructional, interactive exercise teaches public health practitioners epidemiologic skills in outbreak investigation and allows them to apply and practice those skills.

"Gastroenteritis at a University in Texas" is the third in the Foodborne Disease Outbreak Investigation Case Study Series. Other case studies include "Botulism in Argentina" (released in 2002) and "*E. coli* O157:H7 Infection in Michigan" (released in 2004). The three case studies cover a range of outbreak investigation topics. Because these case studies are self-instructional, students can complete them at their own convenience and pace. Students can select which learning activities to undertake and focus on areas in which they are deficient or that are most relevant to their job activities.

The Foodborne Disease Outbreak Investigation series was created for students with knowledge of basic epidemiologic and public health concepts. Each case study was developed in collaboration with the original investigators and experts from CDC and the Council of State and Territorial Epidemiologists. Students can receive continuing education credits (e.g., CEUs, CMEs, CNEs, and CECHs) for completing each case study. All three case studies can be downloaded for free or purchased on CD-ROM through the Epidemiologic Case Studies website at http://www.cdc.gov/epicasestudies.



SOURCE: National Health Interview Survey annual data files, 2001–2004. Available at http://www.cdc.gov/nchs/nhis.htm.

186

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending February 18, 2006 (7th Week)*

	Current	Cum	5-year weeklv	Total of	cases rec	orted for	r previou	s years	
Disease	week	2006	average [†]	2005	2004	2003	2002	2001	States reporting cases during current week (No.
Anthrax			0				2	23	
Botulism:			0				~	20	
foodborne	_	_	0	20	16	20	28	39	
infant		2	1	87	87	76	69	97	
other (wound & unspecified)	1	8	0	24	30	33	21	19	CA (1)
Brucellosis	2	9	2	104	114	104	125	136	MI (1), CA (1)
Chancroid	2	3	1	27	30	54	67	38	(1), OA(1)
Cholera	_		0	6	5	2	2	30	
Cyclosporiasis [§]	_	5	2	735	5 171	2 75		3 147	
	_			735	171		156		
Diphtheria	_	_	_	_	_	1	1	2	
Domestic arboviral diseases ^{§1} :				74	110	100	101	100	
California serogroup	_	_	_	71	112	108	164	128	
eastern equine	_	_	—	21	6	14	10	9	
Powassan	_	_		1	1		1	N	
St. Louis	—	_	—	10	12	41	28	79	
western equine	—	_	—	_	_	_	_	_	
Ehrlichiosis [§] :									
human granulocytic		3	1	722	537	362	511	261	
human monocytic	2	26	1	476	338	321	216	142	MD (2)
human (other & unspecified)	_	_	0	119	59	44	23	6	
Haemophilus influenzae,**									
invasive disease (age <5 yrs):									
serotype b	_	1	0	8	19	32	34	_	
nonserotype b	1	6	4	115	135	117	144	_	NY (1)
unknown serotype	5	22	4	201	177	227	153	_	NY (1), PA (1), MI (2), WA (1)
Hansen disease	_	7	1	88	105	95	96	79	
Hantavirus pulmonary syndrome§	_	1	0	22	24	26	19	8	
Hemolytic uremic syndrome, postdiarrheal§	1	6	2	204	200	178	216	202	CA (1)
Hepatitis C viral, acute	5	85	33	751	713	1,102	1,835	3,976	NY (2), FL (1), CO (2)
HIV infection, pediatric (age <13 yrs) ^{§††}	_	_	5	255	436	504	420	543	(=), · = (·), · • • (=)
Influenza-associated pediatric mortality ^{§,§§,¶¶}	_	9	1	49		N	N	N	
Listeriosis	10	47	8	823	753	696	665	613	NY (1), OH (2), MN (1), MD (1), FL (1), UT (1), CA (3)
Measles		1*		63	37	56	44	116	(1), (1), (1), (1), (1), (1), (1), (1),
Meningococcal disease, ^{†††} invasive:				00	07	00		110	
A, C, Y, & W-135	3	29	7	276	_	_	_	_	FL (2), WA (1)
serogroup B	1	14	4	153	_	_	_	_	WA (1)
other serogroup	1	2	1	19	_	_	_	_	WA (1)
	1	29	5	291	258	231	270	266	OU(4)
Mumps	I								OH (1)
Plague	_	_	_	7	3	1	2	2	
Poliomyelitis, paralytic	_	_		1					
Psittacosis [§]	_		0	21	12	12	18	25	
Q fever [§]	_	10	1	132	70	71	61	26	
Rabies, human		_	_	2	7	2	3	1	
Rubella	—	_	0	11	10	7	18	23	
Rubella, congenital syndrome	—	_	0	1	_	1	1	3	
SARS-CoV ^{§,§§}	_	_	0	_	_	8	N	N	
Smallpox [§]	—	_	_	—	_	—	—	—	
Streptococcal toxic-shock syndrome§	6	14	3	103	132	161	118	77	OH (2), NC (4)
Streptococcus pneumoniae,§									
invasive disease (age <5 yrs)	16	98	15	1,012	1,162	845	513	498	MA (1), NY (2), OH (2), IN (4), MI (1), AR (1),
									OK (2), CO (3)
Syphilis, congenital (age <1 yr)	_	24	8	307	353	413	412	441	
Tetanus	_	1	0	20	34	20	25	37	
Toxic-shock syndrome (other than streptococca	al)§ 1	8	2	90	95	133	109	127	NC (1)
Trichinellosis	· _	2	0	18	5	6	14	22	
Tularemia§	_	3	0	135	134	129	90	129	
Typhoid fever	5	26	6	298	322	356	321	368	MO (1), GA (1), FL (2), CA (1)
Vancomycin-intermediate Staphylococcus aure			_	200		N	N	N	
Vancomycin-resistant <i>Staphylococcus aureus</i> [§]	_	_	_	_	1	N	N	N	
Yellow fever						1.4	1	1.4	

-: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

* Incidence data for reporting years 2004, 2005, and 2006 are provisional, whereas data for 2001, 2002, and 2003 are finalized.

[†] Calculated by summing the incidence counts for the current week, the two weeks preceding the current week, and the two weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf. Not notifiable in all states.

§

1 Includes both neuroinvasive and non-neuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious

 Includes both heuroinvasive and instruction date. Optice working neuroperiod to the Enterthy
 Diseases (ArboNET Surveillance).
 ** Data for *H. influenzae* (all ages, all serotypes) are available in Table II.
 ⁺⁺ Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Data for HIV/AIDS are available in Table IV quarterly. Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases.

§§

11 Of the 14 cases reported since October 2, 2005 (week 40), only 12 occurred during the current 2005–06 season.

*** No measles cases were reported for the current week.

ttt Data for meningococcal disease (all serogroups and unknown serogroups) are available in Table II.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending February 18, 2006, and February 19, 2005 (7th Week)*

			Chlamydi	a⁺			Coccid	ioidomyc	osis			Cryp	tosporidio	sis	
		Previou	s 52 weel	<u>(s</u> Cum	Cum		Previous §		Cum	Cum		Previous	52 weeks	Cum	Cum
Reporting area United States	week 8,696	Med 18,483	Max 21,772	2006	2005	39	Med 76	Max 799	2006 313	2005 663	22	Med 70	Max 851	2006 264	2005 234
New England Connecticut Maine Massachusetts New Hampshire Rhode Island Vermont [§]	360 — 273 1 59 27	599 150 41 276 34 64 19	1,513 1,176 74 417 64 99 43	3,190 229 221 1,925 194 446 175	3,866 789 301 1,925 245 458 148	N N 		0 0 0 0 0 0 0 0	N N N 	N N 	1 — — 1 —	4 0 2 0 0 0	34 14 2 16 3 5 5	11 2 2 4 2 	12 3 1 3
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	1,223 53 535 323 312	2,264 361 498 674 706	3,537 529 1,601 1,189 1,085	11,058 863 1,958 4,174 4,063	14,374 2,528 2,003 4,785 5,058	N N N	0 0 0 0	0 0 0 0	N N N	N N N	3 2 1	10 0 3 2 4	601 11 562 15 21	48 — 12 28	39 2 8 12 17
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	1,043 	3,077 882 387 542 804 380	4,060 1,700 558 1,015 1,446 495	14,906 3,759 2,673 4,628 2,658 1,188	19,277 4,645 2,806 2,528 6,471 2,827	1 	0 0 0 0 0	3 0 3 1 0	4 2 N	1 N 1 N	5 1 4 	12 1 1 2 4 4	162 16 13 7 109 38	50 4 2 11 26 7	44 8 2 5 14 15
W.N. Central Iowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	375 — 245 74 1 55	1,109 142 145 227 437 98 24 52	1,302 221 263 294 525 200 48 119	6,148 932 971 453 2,645 605 179 363	7,967 888 1,124 1,704 3,025 689 158 379	N N N	0 0 0 0 0 0 0	3 0 3 1 1 0 0	N N N N	N N N	2 - 	8 1 2 2 0 0 0	51 11 5 10 37 2 1 4	28 3 5 14 5 1 	32 6 4 6 14 2
S. Atlantic Delaware District of Columbia Florida Georgia Maryland North Carolina [§] Virginia [§] West Virginia	2,729 61 	3,382 68 67 862 600 358 533 328 425 46	4,677 92 103 1,008 1,135 525 1,743 1,418 841 355	18,520 482 105 5,631 294 2,414 4,784 1,303 2,798 709	23,682 427 500 5,672 3,393 2,277 4,660 3,204 3,251 298	N N N N N		1 0 0 1 0 0 0 0	2 N 2 N 2 N	N N N N N	9 2 3 4	12 0 5 2 0 1 0 1 0	53 2 3 28 12 4 10 4 8 3	88 4 30 28 4 20 	45 16 11 5 7 2 4
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	947 — 177 260 510	1,343 314 158 385 456	2,188 1,048 408 801 624	7,582 1,402 1,375 1,495 3,310	9,200 1,785 1,777 2,713 2,925	 N 	0 0 0 0	0 0 0 0	 N	N N	 	3 0 1 0 0	21 3 20 1 4	3 2 1 	6 3 1 1
W.S. Central Arkansas Louisiana Oklahoma Texas [§]	217 210 7 —	1,936 168 268 218 1,316	3,188 340 760 2,023 1,820	8,071 1,011 280 1,167 5,613	16,428 1,218 1,898 1,516 11,796	 N	0 0 0 0	1 0 1 0 0	 	 	1 1 	2 0 0 0 1	30 1 21 10 8	18 1 2 7 8	9 - 1 3 5
Mountain Arizona Colorado Idaho [§] Montana Nevada [§] New Mexico [§] Utah Wyoming	76 71 — — — 5 —	1,065 327 254 25 41 140 108 87 23	1,561 516 376 236 171 465 281 132 43	4,402 2,162 991 — 808 270 171	7,999 2,997 1,964 224 350 1,015 733 559 157	N N N 	58 55 0 0 1 0 0 0	204 204 0 0 4 2 3 2	16 N N 9 5 2	382 363 N N 15 3 1	1 — — — — 1	2 0 1 0 0 0 0 0	8 1 3 2 3 2 3 2 3 2	6 2 1 3	13 3 4 — 3 2 1
Pacific Alaska California Hawaii Oregon [§] Washington	1,726 67 1,298 — 361	3,167 77 2,447 105 168 366	4,239 121	17,078 361 13,013 638 786 2,280	21,852 446	38 	28 0 28 0 0 0	710 0 710 0 0 0	291 291 N	280 280 N	 	6 0 3 0 1 0	49 2 14 1 20 35	12 — — 12 —	34
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U -	0 0 76 4	0 0 141 12	U U 490	U U 466 63	U U N	0 0 0 0	0 0 0 0	U U N	U U N	U U N	0 0 0 0	0 0 0 0	U U N	U U N

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting years 2006 and 2006 are provisional. * Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Because of a technical problem with hardware, NEDSS data from these states are not included this week.

			aiardiasis					Gonorrhea			Ha		s influenza es, all sero	,	ve
	Current	Previous			Cum	Current		52 weeks		Cum	Current	Previous		Cum	Cum
Reporting area United States	week 177	Med 321	Max 686	2006 1,348	2005 1,899	3,266	Med 6,225	Max 7,443	2006 32,310	2005 43,114	20	Med 38	<u>Max</u> 77	2006 231	2005 322
New England Connecticut Maine Massachusetts New Hampshire Rhode Island Vermont [†]	2 — 2 — 	27 0 4 12 1 0 3	90 65 11 34 7 25 11	70 	1,833 118 1 16 84 4 13	5,200 56 46 3 6 1	103 36 2 50 4 8 1	7,443 280 233 7 86 9 25 4	555 64 15 359 38 72 7	736 270 16 364 19 64 3		3 0 0 2 0 0 0 0	12 6 1 5 3 4 1	13 — 1 10 1 — 1	18 3 1 11 — 3
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	33 5	66 7 22 16 16	205 15 176 33 29	256 100 67 89	390 73 99 110 108	316 34 133 75 74	647 110 123 181 211	982 166 417 405 339	3,328 368 626 1,033 1,301	4,287 778 708 1,311 1,490	6 5 1	8 2 1 3	23 5 19 5 8	61 16 19 26	66 9 18 14 25
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	27 — N 5 22 —	53 13 0 14 15 12	102 32 0 29 34 33	201 8 N 71 105 17	346 82 N 98 71 95	789 — 162 514 55 58	1,261 364 154 228 371 108	1,801 729 234 581 682 158	7,045 1,501 1,227 2,788 1,084 445	7,680 1,802 1,156 865 3,071 786	5 _ 2 3 _	5 1 0 2 0	10 5 6 3 6 3	29 1 7 8 11 2	56 17 6 7 22 4
W.N. Central lowa Kansas Minnesota Missouri Nebraska† North Dakota South Dakota	34 29 _5 	37 5 4 16 9 1 0 2	142 14 9 113 32 5 3 7	143 24 15 48 43 4 1 8	141 34 18 17 50 19 	132 — — 110 15 1 6	356 30 47 63 182 21 2 6	461 54 99 241 40 5 15	1,992 172 288 130 1,206 130 15 51	2,543 189 388 491 1,238 185 9 43		2 0 0 0 0 0 0 0	7 1 2 5 7 1 2 0	11 9 1 	15 — 5 7 2 —
S. Atlantic Delaware District of Columbia Florida Georgia Maryland North Carolina [†] Virginia [†] West Virginia	32 2 29 1 	48 1 19 10 4 0 2 9 0	84 3 6 40 24 11 0 9 38 6	214 2 5 116 41 27 N 8 14 1	297 9 4 101 89 21 N 11 58 4	1,132 16 — 370 2 116 348 87 165 28	1,480 18 40 394 271 141 276 134 146 13	2,199 40 67 503 586 242 766 783 289 34	7,524 181 87 2,643 157 1,055 2,289 497 487 128	10,643 109 314 2,539 1,544 959 2,417 1,428 1,239 94	7 	8 0 2 2 1 1 1 1 0	22 0 12 6 5 11 3 7 3	64 — 17 14 12 12 6 3	82 — 17 27 13 18 1 3 3 3
E.S. Central Alabama [†] Kentucky Mississippi Tennessee [†]	3 3 N 	7 3 0 0 4	19 13 0 0 11	34 26 N 8	57 32 N 25	308 — 57 85 166	519 164 55 133 170	868 491 107 225 284	3,002 722 485 629 1,166	3,682 1,112 551 866 1,153		2 0 0 2	8 2 3 0 5	10 3 7	12 1 — 11
W.S. Central Arkansas Louisiana Oklahoma Texas [†]	6 2 4 N	5 1 1 3 0	23 5 5 16 0	23 7 3 13 N	28 12 6 10 N	125 114 11 —	789 85 147 80 476	1,230 187 461 713 632	3,217 637 210 379 1,991	6,550 628 1,107 686 4,129	 	2 0 0 1 0	7 2 3 5 1	15 2 1 12 —	16 11
Mountain Arizona Colorado Idaho† Montana Nevada† New Mexico† Utah Wyoming	10 6 1 3	27 2 9 2 1 2 1 7 0	58 12 26 12 7 6 6 28 28 2	116 	139 35 47 18 6 7 6 19 1	18 18 — — — — — — — — —	223 72 57 1 2 54 21 14 2	479 166 90 10 9 195 48 22 6	1,250 539 319 — 309 — 55 28	1,718 637 411 12 19 412 139 82 6	1 — — — — 1	3 1 0 0 0 0 0 0	19 9 4 1 0 3 4 2 2	19 12 1 3 3 	40 16 10 5 6 1 1
Pacific Alaska California Hawaii Oregon [†] Washington	30 24 2 4	60 2 41 1 6 5	169 6 84 6 21 80	291 1 233 4 46 7	383 5 309 15 40 14	390 5 313 — 72	787 10 650 19 30 72	1,049 23 805 36 58 210	4,397 41 3,587 109 134 526	5,275 68 4,423 135 194 455	1 — — — 1	2 0 1 0 1 0	20 19 7 2 4 4	9 2 1 5 1	17 2 4 1 10 —
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U —	0 0 3 0	0 0 14 0	U U 1	U U 9	U U —	0 0 6 0	0 0 16 20	U U 41	U U 43 26	U U —	0 0 0 0	0 0 1 0	U U 	U U —

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 18, 2006, and February 19, 2005 (7th Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median.

Max: Maximum.

⁸ Incidence data for reporting years 2005 and 2006 are provisional.
 ⁹ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Because of a technical problem with hardware, NEDSS data from these states are not included this week.

MMWR

				Hepat											
	0	Description	A	0	0	Ourseat	Duraniana	B	0	0	0		gionellosi		0
Reporting area	week	Previous Med	52 weeks Max	2006 S	Cum 2005	week	Previous Med	Max	Cum 2006	Cum 2005	week	Previous Med	52 weeks Max	Cum 2006	Cum 2005
United States	46	78	182	392	524	25	100	155	384	766	16	37	111	126	156
New England Connecticut Maine Massachusetts New Hampshire Rhode Island Vermont [†]	 	8 1 5 1 0 0	23 3 14 12 4 2	33 2 1 21 5 1 3	62 9 49 4 	2 - 2 -	5 0 4 0 0	12 5 10 3 2 1	30 27 3 	35 9 23 2 1	 	2 0 1 0 0 0	11 8 1 5 1 7 3	5 1 2 — 1	4 4
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	3 1 2	12 3 2 5 1	23 11 17 12 6	22 — 5 9 8	97 18 8 48 23	2 1 1	13 5 2 2 4	37 26 10 7 8	25 — 3 5 17	142 76 8 21 37	2 1 1	11 1 3 2 5	53 12 25 20 17	34 1 10 4 19	50 8 12 1 29
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	3 - 3 -	7 1 2 1 1	18 9 10 11 7 5	31 17 11 1	58 25 2 13 13 5	2 — 1 1	10 2 0 3 2 0	25 7 11 7 8 6	32 — 16 14 2	77 23 1 28 22 3	1 - 1 	6 0 2 3 0	23 2 5 6 19 2	16 7 8	39 7 3 10 17 2
W.N. Central lowa Kansas Minnesota Missouri Nebraska† North Dakota South Dakota	 	2 0 0 0 0 0 0 0	31 2 3 31 5 3 0 1	13 	12 2 6 2	1 1 	5 0 0 3 0 0 0	13 2 3 6 7 2 0 1	9 2 7 	31 1 4 19 7 —	 	1 0 0 0 0 0 0 0	12 1 10 3 1 1 6	2 - 2 -	5 - 5 -
S. Atlantic Delaware District of Columbia Florida Georgia Maryland North Carolina [†] Virginia [†] West Virginia	26 — 4 1 20 —	13 0 5 1 2 0 1 1 0	33 1 2 18 6 6 18 3 7 2	76 1 26 5 13 28 2 	65 1 29 18 5 3 3 6	12 1 	24 1 9 2 2 0 3 2 0	52 6 4 21 6 8 19 9 12 11	113 1 57 5 22 19 6 2	220 7 71 47 25 26 16 26 26 2	10 	8 0 2 0 2 0 0 1	19 4 2 6 3 9 3 2 8 3	40 1 19 2 13 3 - 2 -	34 11 3 11 5 3 1
E.S. Central Alabama [†] Kentucky Mississippi Tennessee [†]	 	3 0 0 2	16 6 3 2 13	10 9	27 3 1 6 17	 	7 1 1 2	20 7 6 4 12	23 8 6 3 6	43 14 10 5 14	 	1 0 0 1	6 2 4 1 4	2 2	2 2 —
W.S. Central Arkansas Louisiana Oklahoma Texas [†]	1 — 1	6 0 1 0 4	19 3 5 1	8 2 5	36 — 11 1 24	 	12 1 1 0 9	35 3 5 5 33	91 2 87	65 11 10 4 40	 	0 0 0 0	4 1 2 3 3	2 2 	
Mountain Arizona Colorado Idaho [†] Montana Nevada [†] New Mexico [†] Utah Wyoming	1 	6 3 0 0 0 0 0 0	21 20 5 3 1 2 3 3 0	13 7 1 2 2 1	53 30 7 5 4 2 3 2	 	9 5 1 0 1 0 0 0 0	39 34 2 2 4 3 5 1	13 7 1 3 1 1	73 48 3 4 3 7	1 1	2 0 0 0 0 0 0 0 0	8 3 2 1 2 1 2 1 2	5 1 3 1	10 3 1 2 1 1 2
Pacific Alaska California Hawaii Oregon [†] Washington	12 — 11 — —	15 0 13 0 1 1	148 2 147 2 4 11	186 — 175 4 3 4	114 1 92 3 9 9	6 	10 0 6 0 2 0	49 1 34 1 5 11	48 38 9 1	80 	2 2 N	1 0 1 0 0	10 1 10 1 0 0	20 20 N	12 12 N
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U —	0 0 1 0	1 0 6 0	U U —	U 7	U U —	0 0 1 0	0 0 6 0	U U —		U U —	0 0 0 0	0 0 0 0	U U —	U U — —

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 18, 2006, and February 19, 2005 (7th Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median.

Max: Maximum.

* Incidence data for reporting years 2005 and 2006 are provisional. © Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Because of a technical problem with hardware, NEDSS data from these states are not included this week.

(7th Week)*			Lyme diseas	20				Malaria		
	Current	Previous	S 52 weeks	Cum	Cum	Current	Previous	52 weeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	31	291	1,316	290	915	9	23	46	113	154
New England	_	43	209	13	75	—	1	12	5	4
Connecticut Maine	_	9 2	154 25	9 1	4	_	0 0	10 1	_	_
Massachusetts	_	12	141	_	61	_	0	4	4	4
New Hampshire Rhode Island	_	3 0	17 12	3	9	_	0	1 1	_	_
Vermont [†]	_	0	5	_	1	_	0	2	1	_
Mid. Atlantic	17	183	918	149	623	2	6	15	20	44
New Jersey	_	35	305	6	219	_	1	7	_	13
New York (Upstate) New York City	15	48 0	781 0	52	85	1	1 3	6 8	4 10	4 22
Pennsylvania	2	59	458	91	319	1	1	2	6	5
E.N. Central	1	13	156	9	37	_	2	6	11	15
Illinois	_	0	6	_		—	0	2	3	5
Indiana Michigan	_	0 1	4 7	2	1	_	0 0	1 2	1	6
Ohio	1	1	5	2	11	_	0	3	4	2
Wisconsin	—	10	148	5	24	—	0	2	3	2
W.N. Central	2	13	99	10	5	—	0	5	4	7
lowa Kansas	_	1 0	8 3	1	3 2	_	0 0	1 1	_	2 1
Minnesota	2	9	96	8		_	0	3	2	1
Missouri	_	0	2	1	—	_	0	3	1	3
Nebraska [†] North Dakota	_	0 0	1 0	_	_	_	0 0	2 0	_	_
South Dakota	_	0	1	_	_	_	0	1	1	_
S. Atlantic	5	32	125	83	160	2	6	15	35	25
Delaware	_	9	37	28	66	—	0	1	_	1
District of Columbia Florida	1 2	0 1	2 8	2 6	1 7	1	0 1	2 6	4	4
Georgia	_	0	1	_	_	1	0	6	11	6
Maryland	2	16	86	42	74	—	1	9	13	8
North Carolina South Carolina [†]	_	0 0	5 3	5	7 3	_	0 0	8 2	3 1	_2
Virginia [†]	_	3	20	_	2	_	0	5	3	3
West Virginia	—	0	6	_	_	_	0	2	_	1
E.S. Central	—	1	4	_	2	—	0	2	1	3
Alabama [†] Kentucky	_	0 0	1 1	_	_	_	0 0	1 2	1	1
Mississippi	_	0	0	_	_	—	0	0	—	—
Tennessee [†]	—	0	4	_	2	—	0	2	—	1
W.S. Central	—	1	8	—	3	—	1	9	4	15
Arkansas Louisiana	_	0 0	2 2	_	1	_	0 0	2 1	_	1
Oklahoma	_	0	0	—	_	—	0	6	1	_
Texas [†]	_	0	7	_	2	_	1	9	3	13
Mountain	—	0	4	—	—	1	0	6	6	11
Arizona Colorado	_	0	4 1	_	_	_	0	4 3	2	2 5
Idaho†	—	Ō	1	—	_	_	Ō	Ō	_	—
Montana Nevada [†]	_	0 0	0 2	_	_	_	0 0	0 2	_	_
New Mexico [†]	_	0	1	_	_	_	0	1	_	1
Utah	_	0	1	_	—	1	0	2	4	2
Wyoming	_	0	1	_	_		0	1		1
Pacific Alaska	6	3 0	10 1	26	10 1	4	4 0	12 1	27 1	30 1
California	6	2	10	26	8	4	3	9	22	28
Hawaii	Ν	0	0	Ν	N	_	0	4		_
Oregon [†] Washington	_	0 0	2 3	_	1	_	0	2 4	2	1
	U	0	0	U	 U	 U	0	4	U	 U
American Samoa C.N.M.I.	U	0	0	U	U	U	0	0	U	U
Guam	_	0	0	_	_	_	0	0	_	_
Puerto Rico U.S. Virgin Islands	N	0 0	0 0	N	N	_	0 0	1 0	_	_
o.o. virgin islanus	_	0	U			_	0	0		_

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 18, 2006, and February 19, 2005 (7th Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

⁸ Incidence data for reporting years 2006 and 2006 are provisional.
 ⁹ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Because of a technical problem with hardware, NEDSS data from these states are not included this week.

MMWR

	Meningococcal disease, invasive														
			serogrou					oup unkno					Pertussis		
Reporting area	week	Previous Med	52 week Max	s Cum 2006	Cum 2005	Current E week	Med	Max	Cum 2006	Cum 2005	week	Previous Med	52 weeks Max	Cum 2006	Cum 2005
United States	10	20	56	133	192	6	13	46	88	101	111	424	618	1,231	3,311
New England Connecticut Maine Massachusetts New Hampshire Rhode Island Vermont [†]	 	1 0 0 0 0 0	5 3 1 3 2 2 1	6 2 2 2 —	15 1 10 1 2		1 0 0 0 0 0	2 2 1 2 2 0 1	6 2 2 2 	5 1 2 1 1	 	26 0 19 1 0 1	49 4 39 15 8 6	172 160 9	198 14 6 139 — 39
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	1 — — 1	3 0 0 1	14 4 6 5 3	25 — 2 11 12	27 7 6 4 10	1 1	2 0 0 1	13 4 5 5 3	23 — 1 11 11	20 7 2 4 7	24 — 12 — 12	23 3 9 2 7	102 9 92 6 28	139 6 41 92	264 34 73 12 145
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	1 - 1	2 0 0 0 0 0	9 2 3 3 5 2	7 2 2 3	19 5 2 3 4 5	1 — — 1	1 0 0 0 0	6 2 3 4 2	6 2 1 3	18 5 2 4 5	15 5 9 	63 14 5 4 20 21	121 31 23 26 43 40	176 7 8 29 124 8	858 151 9 35 362 301
W.N. Central lowa Kansas Minnesota Missouri Nebraska† North Dakota South Dakota		1 0 0 0 0 0 0 0	5 2 1 2 3 1 1 1	6 - 3 -	12 3 1 2 5 1 		0 0 0 0 0 0 0	3 2 1 2 1 2 1 1 0	2 - 2 -	4 1 2 1 	 	58 9 11 0 9 2 0 2	205 55 29 148 39 12 28 9	171 25 74 62 8 2 —	538 203 58 93 84 47 16 37
S. Atlantic Delaware District of Columbia Florida Georgia Maryland North Carolina South Carolina [†] Virginia [†] West Virginia	3 3 	4 0 1 0 0 0 0 0 0	13 1 0 7 2 2 11 2 3 1	28 1 10 1 3 11 2	29 9 6 2 4 6 2	1 1 	2 0 1 0 0 0 0 0 0	7 1 6 2 1 3 1 3 1	11 1 4 1 3 - 1	12 	8 - 5 - 1 2 -	24 0 4 1 4 0 6 1	90 1 3 14 3 8 21 17 72 12	107 1 2 39 33 19 13 	178 10 15 6 44 14 72 14 3
E.S. Central Alabama [†] Kentucky Mississippi Tennessee [†]	 	1 0 0 0	4 1 3 1 2	4 1 - 2	7 2 2 3	 	1 0 0 0	4 1 3 1 1	2 1 1 	4 2 		8 1 3 1 3	25 9 10 4 17	15 8 2 1 4	76 20 19 12 25
W.S. Central Arkansas Louisiana Oklahoma Texas [†]	1 1 —	2 0 0 0 0	7 3 3 3 4	10 2 6 2 —	18 4 8 3 3	1 1 —	0 0 0 0	5 2 2 3 3	6 2 4 	4 1 2 	4 4 	40 5 0 36	111 19 3 1 98	42 10 1 2 29	48 6 3
Mountain Arizona Colorado Idaho [†] Montana Nevada [†] New Mexico [†] Utah Wyoming	1 1	2 0 0 0 0 0 0 0	7 5 2 2 0 2 2 2 0	10 	16 5 7 1 1	1 1	1 0 0 0 0 0 0 0 0	5 5 2 0 1 2 1 0	4 2 2 2	9 2 7 	48 28 	74 15 24 3 8 0 3 12 1	145 86 43 19 29 8 9 35 4	350 	609 41 298 43 150 4 42 26 5
Pacific Alaska California Hawaii Oregon [†] Washington	3 1 	4 0 2 0 0 0	28 1 11 2 4 25	37 	49 21 3 18 7	1 1 	3 0 2 0 0 0	13 1 11 2 11	28 25 1 2	25 21 1 2 1	12 1 11	69 2 40 3 6 11	272 12 146 10 26 178	59 15 21 17	542 5 319 19 164 35
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U —	0 0 0 0	1 0 2 0	 	 _1	U U —	0 0 0 0	1 0 2 0	U U 	U U 1	U U 	0 0 0 0	0 0 2 0	U U 	U U 1

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 18, 2006, and February 19, 2005 (7th Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. N: Not notifiable. -: No reported cases. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting years 2005 and 2006 are provisional. [§] Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Because of a technical problem with hardware, NEDSS data from these states are not included this week.

Max: Maximum.

(7th Week)*															
			bies, anim				ocky Mour		ted fever				Imonellos	is	
Dementing and	Current				Cum		Previous !		Cum	Cum		Previous		Cum	Cum
Reporting area United States	week 35	105	Max 160	2006 297	2005 717	week 3	Med 34	Max 98	2006 162	2005 63	302	Med 856	Max 1,449	2006 2,801	2005 3,047
New England Connecticut Maine Massachusetts New Hampshire Rhode Island Vermont [†]	2 2 	13 3 1 5 0 1	33 13 4 22 3 4 7	42 8 6 22 1 1 4	79 11 54 2 	N	0 0 0 0 0 0 0	1 0 1 1 1 0	N 	 	1 — — 1 —	40 9 3 20 2 0 1	76 25 8 38 12 15 10	122 25 2 81 8 4 2	132 26 8 80 9 9
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	5 N 5	18 0 12 0 7	40 0 24 3 22	66 N 45 21	66 N 25 4 37	 	2 0 0 1	8 6 2 2 6	1 — 1 —	3 1 1 1	26 — 21 1 4	95 16 22 24 30	183 45 146 43 61	267 2 58 79 128	350 72 58 108 112
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	 	3 1 0 0 0	19 4 3 4 13 3	2 — 1 1	6 1 2 2	1 — — 1	0 0 0 0 0	3 1 1 3 1	1 - 1	1 — — 1	36 6 30 	93 29 10 17 23 15	243 160 71 35 52 45	282 13 30 64 131 44	364 102 11 81 89 81
W.N. Central Iowa Kansas Minnesota Missouri Nebraska [†] North Dakota South Dakota		7 1 1 1 0 0 1	23 10 5 7 0 4 6	15 3 1 1 2 5	30 6 4 11 4 — 5	 	2 0 0 1 0 0 0	16 2 1 14 2 0 2	2 - 2 -	3 - 3 -	9 - 9 -	43 7 10 14 2 0 2	91 18 17 31 40 8 5 11	185 31 21 36 73 11 13	192 44 19 41 59 16 2 11
S. Atlantic Delaware District of Columbia Florida Georgia Maryland North Carolina South Carolina [†] Virginia [†] West Virginia	21 — 3 15 1 2 —	30 0 5 6 8 9 0	49 0 14 9 16 19 1 26 13	121 — 21 16 6 23 — 47 8	407 201 31 35 56 4 78 2		16 0 0 1 2 5 1 1 0	94 2 1 9 7 87 6 10 2	155 — 2 14 4 133 2 —	42 — 2 1 35 3 —	125 — 69 6 11 39 —	253 2 1 99 32 14 30 21 19 2	511 9 7 230 75 39 114 146 66 13	925 5 7 422 158 67 222 28 15 1	846 6 338 110 64 187 70 63 8
E.S. Central Alabama [†] Kentucky Mississippi Tennessee [†]	4 3 1	3 1 0 1	9 5 3 1 5	25 8 — 17	11 10 — 1	 	5 0 0 3	25 9 1 3 19	1 — — 1	1 — — 1	12 12 —	55 13 7 13 15	134 39 26 66 40	167 84 26 12 45	182 64 21 24 73
W.S. Central Arkansas Louisiana Oklahoma Texas [†]	 	14 0 0 1 12	42 3 0 7 39	8 1 7	86 6 9 71	2 2 —	2 0 0 0 0	32 32 2 23 7	2 2 	1 	30 24 6 	79 12 15 7 43	157 67 42 26 121	261 50 18 31 162	236 32 60 27 117
Mountain Arizona Colorado Idaho† Montana Nevada† New Mexico† Utah Wyoming	2 2 - - - -	4 2 0 0 0 0 0 0 0 0	19 11 2 12 3 2 1 5 2	12 12 — — — —	27 24 — — 1 2		0 0 0 0 0 0 0 0	8 8 1 2 1 0 1 1		10 8 2 	18 6 — — 8 4	50 13 10 2 3 5 6 1	112 28 45 17 16 8 14 31 12	155 — 67 11 13 15 11 29 9	190 65 52 14 7 22 15 9 6
Pacific Alaska California Hawaii Oregon [†] Washington	1 - - U	4 0 3 0 0 0	15 3 15 0 1 0	6 2 4 U	5 1 4 U		0 0 0 0 0	2 0 1 0 1 0		2 2 	45 37 8	101 1 77 5 7 9	357 5 242 15 23 107	437 12 355 28 28 14	555 9 430 59 26 31
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U —	0 0 1 0	0 0 6 0	U U 9	U U 11	U U N	0 0 0 0	0 0 0 0	U U N	U U N	U U 1	0 0 8 0	2 0 0 23 0	U U 5	U

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending February 18, 2006, and February 19, 2005 (7th Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. Cum: Cumulative year-to-date counts. Med: Median. -: No reported cases. N: Not notifiable.

⁸ Incidence data for reporting years 2005 and 2006 are provisional.
 ⁹ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Because of a technical problem with hardware, NEDSS data from these states are not included this week.

(7th Week)*	Chie	tovin	ducir - 1								Chron	tooocol -			
		a toxin-pro Previous			Cum	Current		nigellosis 52 weeks	Cum	Cum	<u> </u>		bisease, inv 52 weeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	5	50	156	72	161	69	275	452	913	1,193	55	80	151	555	621
New England Connecticut	_	4 1	14 4	6	16 8	1	5 1	15 4	27 3	22 2	 U	3 0	8 0	18 U	25 U
Maine	—	0	5	_	_	_	0	1	—	—	_	0	2	3	2
Massachusetts New Hampshire	_	2 0	8 2	6	7	1	3 0	9 4	23 1	18 1	_	2 0	6 2	10 4	18 1
Rhode Island Vermont [§]	_	0 0	2	_	1	_	0 0	6 4		- - 1	_	0 0	3	1	4
Mid. Atlantic	_	7	24	_	14	7	22	67	51	123	7	16	38	98	135
New Jersey New York (Upstate)	_	1 2	6 16	1	3 6	7	5 4	14 42	31	40 17	5	3 4	9 19	5 30	29 43
New York City Pennsylvania	_	0 2	2 8	_	1 4	_	7 2	22 48	17 3	60 6	2	3 5	9 12	15 48	22 41
E.N. Central Illinois	_	8 1	31 7	13	40 10	9	16 5	78 24	57 4	88 25	7	15 3	41 10	106 9	131 32
Indiana	_	1	7	5	1	_	1	56	5	1	2	1	11	16	13
Michigan Ohio	_	1 2	8 14	2 6	8 13	9	4 2	14 11	21 21	41 10	1 3	6 4	15 14	32 38	52 22
Wisconsin	_	2	15	_	8	—	3	9	6	11	1	1	8	11	12
W.N. Central Iowa	_	7 1	39 10	17 4	26 5	6	38 1	64 9	133 2	98 12	N	5 0	19 0	27 N	21 N
Kansas Minnoacto	_	1 2	4	 13	2 3	2	4 2	20 6	12 11	4 4	_	1	5 15	15	2
Minnesota Missouri	_	1	23 7	5	9	4	22	45	90	57	_	1	6	7	9
Nebraska [§] North Dakota	_	0	4	_	5	_	1 0	9 2	7	14	_	0 0	4 3	4 1	4 2
South Dakota	_	0	2 5	_	2	_	1	17	1 10	1 6	_	0	2	_	4
S. Atlantic Delaware	3	7 0	39 2	10	30	27	44 0	117 2	259	157 1	26	19 0	33 2	166 1	126
District of Columbia	_	0	1	_	_	_	0	2	1	_	1	0	2	3	1
Florida Georgia	3	1	31 6	10	11 5	20 5	22 11	66 32	131 81	77 46	11 3	5 3	12 9	49 40	44 23
Maryland	_	1	5	_	5	2	2	8	18	11	3	4	12	32	29
North Carolina South Carolina§	_	1 0	11 2	9	7	_	2 2	22 6	18 10	6 8	8	1	13 3	21 9	15 7
Virginia [§]	_	2	9	_	2	_	2	9		8	_	2	11	9	5
West Virginia E.S. Central	_	0 3	1 12	3	6	1	0 20	1 54		— 130	1	0 3	5 11	2 19	2 19
Alabama§	_	0	3	_	3	1	3	20	13	30	—	0	0	—	—
Kentucky Mississippi	_	1 0	9 2	3	_	_	6 2	31 7	28 9	6 10	1	0 0	3 0	4	3
Tennessee§	_	1	3	1	3	_	5	46	9 5	84	_	3	8	15	16
W.S. Central Arkansas	_	2 0	9 2	_	6 1	2 1	61 1	121 3	90 6	227 10	8	6 0	16 4	49 1	33 6
Louisiana	_	0	2	_	2	_	2	11	7	24	_	0	1	2	3
Oklahoma Texas [§]	_	0 1	3 4	_	1 2	1	10 45	41 105	17 60	56 137	8	2 3	13 14	32 14	13 11
Mountain Arizona	_	5 0	15 4	6	15 2	2	17 9	47 29	38	78 36	6	12 4	28 16	59	114 53
Colorado	_	1	4 6	6	4	_	3	29 17	12	13	3	4	11	38	38
Idaho [§]	—	1 0	8	_	5	—	0 0	4 1	2	_	—	0 0	2 0	—	1
Montana Nevada§	_	0	2 4	_	1	_	1	6	8	15	_	0	6	_	_
New Mexico [§] Utah	_	0 1	3 7	1	2	2	2 1	9 4	6 9	10 4	3	1 2	6 6	6 14	17 4
Wyoming	_	0	3		1		0	4	9	4		2	1	14	4
Pacific	2	6	52	17	8	14	40	124	203	270	_	2	8	13	17
Alaska California	1	0 1	3 6	 14	1 1	8	0 35	1 90	 147	1 244	_	0 0	0 0	_	_
Hawaii	_	0	4	_	1		1	4	9	4	_	2	8	13	17
Oregon [§] Washington	1	1 1	47 39	3 3	5	6	1 2	27 35	34 13	14 7	N N	0 0	0 0	N N	N N
American Samoa	U	0	0	U	U	U	0	2	U	_	U	0	0	U	U
C.N.M.I. Guam	U	0 0	0 0	U	U	U	0 0	0 0	U	U	U	0 0	0 0	U	U
Puerto Rico	_	0	1	_	—	_	0	1	_	_	N	0	0	N	N
U.S. Virgin Islands	_	0	0	_	_	_	0	0	_	_	_	0	0	_	

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 18, 2006, and February 19, 2005 (7th Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

⁺ Incidence data for reporting years 2005 and 2006 are provisional. ⁺ Incidence data for reporting years 2005 and 2006 are provisional. ⁺ Incidence data for reporting years 2005 and 2006 are provisional. ⁺ Incidence data for reporting years 2005 and 2006 are provisional. ⁺ Incidence data for reporting years 2005 and 2006 are provisional. ⁺ Incidence data for reporting years 2005 and 2006 are provisional. these states are not included this week.

(7th Week)*															
	Streptoc		e <i>umoniae</i> sistant, a		ve disease	Sy	/philis, pri	imary & se	econdary			Varice	ella (chicke	npox)	
Poporting area	Current week	Previous Med	52 week Max	s Cum 2006	Cum 2005		Previous Med		Cum 2006	Cum 2005	Current week	Previous Med	52 weeks Max	Cum 2006	Cum 2005
Reporting area United States	45	49	90	383	370	80	167	213	786	946	692	557	1,778	5,371	3,341
New England Connecticut Maine Massachusetts New Hampshire Rhode Island Vermont [†]	U N —	2 0 1 0 0 0	12 0 6 0 7 2	3 U N 3	21 U N 20 — 1	3 - 3 - -	4 0 2 0 0 0	15 11 5 2 6 1	24 1 19 3 —	25 24 	12 U — 12 —	36 0 5 26 4 0 2	1,128 0 20 86 1,110 0 25	167 U 19 58 90	402 U 55 337 — 10
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	4 N 2 U 2	3 0 1 0 2	10 0 9 0 9	22 N 6 U 16	48 N 13 U 35	8 3 4 1	20 2 12 4	33 7 12 21 7	97 18 13 55 11	130 14 6 90 20	86 — — 86	116 0 0 116	211 0 0 211	845 — — 845	402 — — 402
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	10 6 4 N	11 0 3 1 7 0	31 2 16 3 20 0	86 1 14 65 N	65 — 12 9 44 N	11 	17 8 1 2 4 1	40 31 5 8 11 3	99 28 12 21 32 6	62 13 8 5 32 4	422 — 83 339 —	125 1 0 82 29 9	486 5 245 231 348 27	2,648 2 708 1,849 89	1,343 11 967 264 101
W.N. Central Iowa Kansas Minnesota Missouri Nebraska† North Dakota South Dakota	1 N 	1 0 0 0 0 0 0 0	15 0 15 3 1 1 1	9 N 9 9	9 N 8 1	 	5 0 1 2 0 0 0	9 1 2 5 8 1 1 1	20 4 2 14 —	34 2 5 24 1 	25 N 25 	11 0 0 9 0 0 1	70 0 0 69 1 25 23	274 N 254 8 12	10 N 1 9
S. Atlantic Delaware District of Columbia Florida Georgia Maryland North Carolina South Carolina [†] Virginia [†] West Virginia	30 1 26 3 N N N	21 0 11 5 0 0 0 0 2	41 2 4 34 18 0 0 0 0 8	211 	162 — 88 65 — N — N 9	24 - 9 3 3 4 5	39 0 15 7 6 4 1 3 0	90 2 9 29 47 19 17 8 11 1	190 5 4 96 30 35 5 15	209 2 11 103 8 28 37 9 11 	23 2 — — — — — — — — 21	46 0 0 0 0 0 10 7 18	445 4 6 0 0 0 41 436 61	310 3 — — 83 8 213	294 5 — — — 61 15 213
E.S. Central Alabama [†] Kentucky Mississippi Tennessee [†]	 	3 0 0 3	14 0 5 0 13	20 3 17	24 4 20	6 6	9 3 1 0 4	18 11 4 5 11	49 14 6 5 24	60 32 2 6 20	 N 	0 0 0 0	0 0 0 0	 N 	 N
W.S. Central Arkansas Louisiana Oklahoma Texas [†]	 N	1 0 1 0 0	13 3 11 0 0	12 5 7 N N	32 3 29 N N	7 4 3 —	24 1 3 0 18	38 6 17 6 30	142 11 8 7 116	164 4 23 9 128	31 31 — —	135 0 1 0 130	765 32 32 0 733	655 75 18 562	341 5 336
Mountain Arizona Colorado Idaho† Montana Nevada† New Mexico† Utah Wyoming	N N N N N N N N N N N N N N N N N N N	1 0 0 0 0 0 0 0 0	28 0 0 1 27 0 6 3	20 N N 12 5 3	9 N N 1 5 3	12 11 — — — 1	8 3 1 0 2 1 0 0	17 13 6 3 7 3 1 0	50 32 4 13 - 1	47 18 5 6 8 8 2	93 	47 0 35 0 0 0 3 8 0	118 0 87 0 4 15 38 8	472 	549
Pacific Alaska California Hawaii Oregon [†] Washington	 	0 0 0 0 0	0 0 0 0 0	 	 	9 3 6	33 0 28 0 0 2	56 2 54 2 6 11	115 	215 2 197 2 	 		0 0 0 0 0	 	 N
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	 	0 0 0 0	0 0 0 0	 	 N	U U —	0 0 4 0	0 0 16 0	U U 15 —	U U 13	U U 1	0 0 9 0	0 0 47 0	U U 17 —	U U 51

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending February 18, 2006, and February 19, 2005 (7th Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

⁸ Incidence data for reporting years 2005 and 2006 are provisional.
 ⁹ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Because of a technical problem with hardware, NEDSS data from these states are not included this week.

(7th Week)*	ek)* West Nile virus disease†												
			Veuroinvasi	n-neuroinv	asive								
	Current		52 weeks	Cum	Cum	Current		52 weeks	Cum	Cum			
Reporting area	week	Med	Мах	2006	2005	week	Med	Max	2006	2005			
United States	_	1	152	—	—	_	1	203	—	2			
New England Connecticut	_	0 0	3 2	_	_		0 0	2 1	_	_			
Maine	_	0	2	_	_	_	0	0	_	_			
Massachusetts	_	0	3	_	_	_	0	1	_	_			
New Hampshire Rhode Island	_	0 0	0 1	_	_		0 0	0 0	_	_			
Vermont [§]	_	0	0	_	_	_	0	0	_	_			
Mid. Atlantic	_	0	9	_	_	_	0	3	_	_			
New Jersey	_	0	1	_	_	_	0	2	_	_			
New York (Upstate) New York City	_	0 0	6 2	_	_	_	0 0	1 2	_	_			
Pennsylvania	_	0	3	_	_	_	0	2	_	_			
E.N. Central	_	0	39	_	_	_	0	18	_	_			
Illinois	—	0	25	—	—	—	0	16	_	_			
Indiana Michigan	—	0 0	2 14	_	_	_	0 0	1 3	_	_			
Ohio	_	0	9	_	_	_	0	4	_	_			
Wisconsin	—	0	3	_	—	_	0	2	—	_			
W.N. Central	_	0	26	_	_	_	0	78	_	_			
lowa Kansas	_	0 0	3 2	_	_	N	0 0	5 2	N	N			
Minnesota	_	0	2 5	_	_	N	0	2 5		IN			
Missouri	_	Õ	4	_	_	_	õ	3	_	_			
Nebraska§	—	0	9	—	—	—	0	22	—	—			
North Dakota South Dakota	_	0 0	4 7	_	_	_	0 0	15 33	_	_			
S. Atlantic	_	0	5	_	_	_	0	4	_	_			
Delaware	_	0	1	_	_	_	0	0	_	_			
District of Columbia	_	0	0	_	_	_	0	0	—	_			
Florida Georgia	_	0 0	2 3	_	_	_	0 0	4 3	_	_			
Maryland	_	0	2	_	_	_	0	1	_	_			
North Carolina	_	0	1	_	_	_	0	1	_	_			
South Carolina [§]	_	0	1	_	_	—	0	0	—	_			
Virginia [§] West Virginia	_	0 0	0 0	_	_	N	0 0	0 0	N	N			
E.S. Central	_	0	10	_	_	_	0	5	_	_			
Alabama§	_	0	1	_	_	_	0	2	_	_			
Kentucky	_	0	1	_	_	—	0	0	—	_			
Mississippi Tennessee§	_	0 0	9 3	_	_	_	0 0	5 1	_	_			
W.S. Central	_	0	32	_	_		0	21	_	2			
Arkansas	_	0	3	_	_	_	0	2	_	_			
Louisiana	_	0	20	_	_	—	0	8	—	2			
Oklahoma Texas§	_	0 0	6 16	_	_	_	0 0	3 13	_				
Mountain	_	0	16	_	_	_	0	39	_	_			
Arizona	—	0	8	—	—	—	0	8	—	_			
Colorado Idaho [§]	—	0 0	5 2	—	_		0 0	13	—	_			
Montana	_	0	23	_	_	_	0	3 9	_	_			
Nevada§	—	0	3	—	—	—	0	8	—	_			
New Mexico [§]	—	0 0	3 6	—	—	—	0	4	—	_			
Utah Wyoming	_	0	2	_	_	_	0 0	8 1	_	_			
Pacific	_	0	50	_	_		0	89	_	_			
Alaska	_	0	0	_	_	_	0	0	_	_			
California	—	0	50	—	—	_	0	88	—	—			
Hawaii Oregon§	_	0 0	0 1	_	_	_	0 0	0 2	_	_			
Washington	_	0	0	_	_	_	0	0	_	_			
American Samoa	U	0	0	U	U	U	0	0	U	U			
C.N.M.I.	U	0	0	U	U	U	0	0	U	U			
Guam Puerto Rico	_	0 0	0 0	_	_	_	0 0	0 0	_	_			
U.S. Virgin Islands	_	0	0	_	_	_	0	0	_	_			

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending February 18, 2006, and February 19, 2005 (7th Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

 $_{+}^{*}$ Incidence data for reporting years 2005 and 2006 are provisional.

¹ Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases (ArboNet Surveillance). [§] Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Because of a technical problem with hardware, NEDSS data from


these states are not included this week.


TABLE III. Deaths in 122 U.S. cities.* week ending February 18, 2006 (7th Week)

TABLE III. Deaths	in 122 U.S. cities,* week ending February 18, All causes, by age (years)						2006 (7)		All causes, by age (years)						
-	All						P&I [†]		All						P&I [†]
Reporting Area	Ages	<u>≥65</u>	45-64	25-44	1-24	<1	Total	Reporting Area	Ages	<u>>65</u>	45-64	25-44	1-24	<1	Total
New England Boston, MA	590 153	430 103	114 31	22 8	12 7	12 4	57 13	S. Atlantic Atlanta, GA	1,366 172	824 77	344 47	103 19	37 6	58 23	70 2
Bridgeport, CT	28	22	6	_	_	-	3	Baltimore, MD	148	86	45	12	3	23	13
Cambridge, MA	25	21	4	_	_	_	3	Charlotte, NC	134	81	27	12	7	7	13
Fall River, MA	23	21	1	_	1	_	2	Jacksonville, FL	159	107	34	11	4	3	4
Hartford, CT	48	34	11	_	_	3	7	Miami, FL	193	120	51	13	4	5	13
Lowell, MA	33	26	6	1		_	2	Norfolk, VA	56	32	13	7	2	2	_
Lynn, MA	11	7	2	2	_	_	2	Richmond, VA	56	35	15	3	3	_	2
New Bedford, MA	28	22	6	—	—	—	_	Savannah, GA	56	37	10	3	2	4	2
New Haven, CT	41	30	5	2	1	3	4	St. Petersburg, FL	65	44	14	3	1	3	9
Providence, RI	67	46	14	3	2	2	6	Tampa, FL	210	145	49	12	3	1	11
Somerville, MA	2		2	_	_	_	_	Washington, D.C.	104	53	33	8	2	8	1
Springfield, MA	35	27	6	2	_	_	3	Wilmington, DE	13	7	6	_	_	_	_
Waterbury, CT	33	27	4	2	_	—	3	E.S. Central	858	541	218	62	19	18	63
Worcester, MA	63	44	16	2	1	—	9	Birmingham, AL	195	130	43	12	4	6	20
Mid. Atlantic	1,950	1,362	419	110	26	33	126	Chattanooga, TN	83	52	22	6	1	2	3
Albany, NY	35	23	10	1	_	1	4	Knoxville, TN	104	64	29	5	3	3	6
Allentown, PA	34	30	4	_	_	_	2	Lexington, KY	55	37	14	3	1	_	2
Buffalo, NY	56	34	16	3	1	2	3	Memphis, TN	148	89	44	12	2	1	12
Camden, NJ	34	16	14	1	—	3	1	Mobile, AL	66	49	8	7	2		5
Elizabeth, NJ	16	9	5	2	_	_	_	Montgomery, AL	44	28	11	3	1	1	4
Erie, PA	38	31	6	1			6	Nashville, TN	163	92	47	14	5	5	11
Jersey City, NJ	U 1 100	U	U	U	U	U	U	W.S. Central	1,595	1,055	349	115	44	32	121
New York City, NY Newark, NJ	1,123 61	817 29	223 14	61 12	11 3	11 3	68 4	Austin, TX	120	88	23	7	1	1	9
Paterson, NJ	12	29	4	12		1	-	Baton Rouge, LA	64	46	14	2	2	_	_
Philadelphia, PA	206	107	67	19	7	6	15	Corpus Christi, TX	64	44	12	5	1	2	7
Pittsburgh, PA§	23	18	3	1	_	1	2	Dallas, TX	203	136	39	11	6	11	17
Reading, PA	30	27	2	1	_		2	El Paso, TX	99	69	23	3	2	2	6
Rochester, NY	135	105	21	3	4	2	12	Fort Worth, TX	135	92	23	9	4	7	10
Schenectady, NY	19	13	4	1	_	1	1	Houston, TX	440	266	109	43	17	5	41
Scranton, PA	37	31	5	—	—	1	_	Little Rock, AR New Orleans, LA ¹	64 U	43 U	17 U	3 U		1 U	1 U
Syracuse, NY	27	17	8	1	_	1	1	San Antonio, TX	253	162	59	25	5	2	21
Trenton, NJ	26	18	7	1	—	—	1	Shreveport, LA	36	28	5		3		6
Utica, NY	16	11	3	2	_	_		Tulsa, OK	117	81	25	7	3	1	3
Yonkers, NY	22	19	3	_	_	—	4								
E.N. Central	2,106	1,418	469	131	36	52	142	Mountain Albuquerque, NM	1,060 135	696 92	239 26	74 11	28 5	18 1	92 18
Akron, OH	43	31	9	2	1	—	3	Boise, ID	56	92 45	20	1	1	1	4
Canton, OH	34	20	13			1	4	Colorado Springs, CO		43	23	7	2	1	2
Chicago, IL	326	192	90	24	12	8	28	Denver, CO	102	66	21	9	4	2	8
Cincinnati, OH	88	59	19	4	2	4	12	Las Vegas, NV	278	184	70	19	4	1	27
Cleveland, OH	253	190	49	9	2 3	3 6	12	Ogden, UT	37	22	13	1	1	_	3
Columbus, OH Dayton, OH	203 132	136 95	42 28	16 5	3	1	17 7	Phoenix, AZ	224	143	48	17	8	4	17
Detroit, MI	169	91	49	18	4	7	12	Pueblo, CO	26	22	2	2	_	_	2
Evansville, IN	43	35	7	1	_	_	2	Salt Like City, UT	126	79	28	7	3	8	11
Fort Wayne, IN	79	62	7	3	2	5	3	Tucson, AZ	U	U	U	U	U	U	U
Gary, IN	16	10	3	3	_	_	_	Pacific	1,588	1,118	336	84	33	17	150
Grand Rapids, MI	64	42	16	3	1	2	4	Berkeley, CA	17	8	8	1	_	_	_
Indianapolis, IN	190	126	37	15	2	10	9	Fresno, CA	64	48	13	2	1	_	5
Lansing, MI	52	39	8	4	1	—	4	Glendale, CA	12	6	5	_	1	—	1
Milwaukee, WI	101	58	34	7	_	2	9	Honolulu, HI	42	32	8	_	1	1	
Peoria, IL	54	31	18	4	_	1	2	Long Beach, CA	68	48	16	4		_	13
Rockford, IL	53	42	6	3	1	1	2	Los Angeles, CA	209	131	43	17	13	5	21
South Bend, IN	43	30	7	5 5	1	1	4	Pasadena, CA	17	13	4	9			1
Toledo, OH Youngstown, OH	92 71	71 58	15 12		1	_	2 6	Portland, OR Sacramento, CA	145 178	97 139	32 25	9 11	5 2	2 1	6 19
0								San Diego, CA	140	100	28	9	3	_	11
W.N. Central	732	510	147	39	18	18	49	San Francisco, CA	140	100	28 37	9	3	_	16
Des Moines, IA	73	60	8	1	2	2	3	San Jose, CA	214	160	42	7	1	4	34
Duluth, MN	32	24	8			_	1	Santa Cruz, CA	20	16	4	_			1
Kansas City, KS	34	19	11	2	2	_	3	Seattle, WA	136	91	34	10	_	1	9
Kansas City, MO	102	62	28	8	_	4	5	Spokane, WA	55	41	12	1	_	1	4
Lincoln, NE Minneapolis, MN	61 79	51 55	8	1 4	1 4	2	3 3	Tacoma, WA	121	84	25	7	3	2	9
Omaha, NE	79 109	55 74	14 24	4 9	4		3 12	Total	11,845**	7 05/	2,635	740	253	258	870
St. Louis, MO	80	74 51	24 16	9	2	3	12		11,045	1,904	2,000	740	200	200	070
St. Paul, MN	80 59	40	12	1	1	5	5								
Wichita, KS	103	74	18	6	3	2	4								
				<u> </u>	<u> </u>	_		1							

U: Unavailable. -: No reported cases.

* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its ¹ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
 ¹ Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted.





Beyond historical limits

* No rubella cases were reported for the current 4-week period yielding a ratio for week 7 of zero (0).
[†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at *http://www.cdc.gov/mmwr* or from CDC's file transfer protocol server at *ftp://ftp.cdc.gov/pub/publications/mmwr*. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop K-95, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone 888-232-3228.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

All MMWR references are available on the Internet at http://www.cdc.gov/mmwr. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆U.S. Government Printing Office: 2006-523-056/40024 Region IV ISSN: 0149-2195